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ABSTRACT 
Michael Andrew Kalwat 
 
F-ACTIN REGULATION OF SNARE-MEDIATED INSULIN SECRETION 
 
In response to glucose, pancreatic islet beta cells secrete insulin in a biphasic manner, and 
both phases are diminished in type 2 diabetes.  In beta cells, cortical F-actin beneath the plasma 
membrane (PM) prevents insulin granule access to the PM and glucose stimulates remodeling of 
this cortical F-actin to allow trafficking of insulin granules to the PM. Glucose stimulation 
activates the small GTPase Cdc42, which then activates p21-activated kinase 1 (PAK1); both 
Cdc42 and PAK1 are required for insulin secretion.  In conjunction with Cdc42-PAK1 signaling, 
the SNARE protein Syntaxin 4 dissociates from F-actin to allow SNARE complex formation and 
insulin exocytosis.  My central hypothesis is that, in the pancreatic beta cell, glucose signals 
through a Cdc42-PAK1-mediated pathway to remodel the F-actin cytoskeleton to mobilize 
insulin granules to SNARE docking sites at the PM to evoke glucose stimulated second phase 
insulin secretion.  To investigate this, PAK1 was inhibited in MIN6 beta cells with IPA3 followed 
by live-cell imaging of F-actin remodeling using the F-actin probe, Lifeact-GFP.  PAK1 
inhibition prevented normal glucose-induced F-actin remodeling.  PAK1 inhibition also 
prevented insulin granule accumulation at the PM in response to glucose.  The ERK pathway was 
implicated, as glucose-stimulated ERK activation was decreased under PAK1-depleted 
conditions.  Further study showed that inhibition of ERK impaired insulin secretion and cortical 
F-actin remodeling.  One of the final steps of insulin secretion is the fusion of insulin granules 
with the PM which is facilitated by the SNARE proteins Syntaxin 4 on the PM and VAMP2 on 
the insulin granule.  PAK1 activation was also found to be critical for Syntaxin 4-F-actin complex 
dynamics in beta cells, linking the Cdc42-PAK1 signaling pathway to SNARE-mediated 
exocytosis.  Syntaxin 4 interacts with the F-actin severing protein Gelsolin, and in response to 
vii 
 
glucose Gelsolin dissociates from Syntaxin 4 in a calcium-dependent manner to allow Syntaxin 4 
activation.  Disrupting the interaction between Syntaxin 4 and Gelsolin aberrantly activates 
endogenous Syntaxin 4, elevating basal insulin secretion.  Taken together, these results illustrate 
that signaling to F-actin remodeling is important for insulin secretion and that F-actin and its 
binding proteins can impact the final steps of insulin secretion. 
 
Debbie C. Thurmond, PhD, Chair 
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CHAPTER 1.  INTRODUCTION  
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1.1 GLUCOSE HOMEOSTASIS AND TYPE 2 DIABETES 
 
The disease diabetes has been known for more than two millennia, but most of the 
advancements in our knowledge of the etiology of the disease have come about in the last 150 
years (3).  Diabetes mellitus literally means ‘sweet urine’ and is so named because individuals 
with advanced uncontrolled disease have hyperglycemia that leads to glucose excretion into the 
urine (3).  The maintenance of blood glucose homeostasis is critical for survival, and is controlled 
by the coordination of multiple organs and endocrine systems.  Upon consumption of a meal, 
blood glucose levels increase and pancreatic islet beta cells sense this increase and secrete the 
hormone insulin in response.  Insulin suppresses hepatic glucose production and signals to 
skeletal muscle and adipose tissue to take up the excess blood glucose.  This process maintains 
the blood glucose concentration within a range of about 110-125 mg/dl (5.6-6.9 mM) in humans 
(4).  If both the secretion of insulin and the uptake of glucose by peripheral tissues fail, the 
resulting hyperglycemia leads to type 2 diabetes mellitus (3). 
As of 2011, about 8% of the United States population has been diagnosed with diabetes  
(5). In adults, type 2 diabetes accounts for 90-95% of all diabetes cases, while type 1 diabetes 
accounts for about 5% (5) Distinct from type 2 diabetes, type 1 diabetes occurs when the body’s 
immune system attacks the pancreatic beta cells causing a loss of beta cell mass and a loss of 
insulin secretion.  Accounting for the remaining percentage are cases of maturity-onset diabetes 
of youth and gestational diabetes.  Maturity-onset diabetes of youth is caused by heritable genetic 
mutations that account for 1-5% of all diabetes cases (5).  Gestational diabetes occurs in up to 
18% of pregnant women, of those women,  5% to 10% of women will develop type 2 diabetes 
immediately after pregnancy, and the remaining 8-13% will have ~ 60% chance of developing 
diabetes in the following 10-20 years (5).  Insulin resistance in the liver can also contribute to 
hyperglycemia in diabetes due to a failure to suppress hepatic glucose output (6). 
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Current research suggests that in response to peripheral insulin resistance and elevated 
blood glucose levels, beta cells compensate by increasing mass, resulting in increased insulin 
production (7).  After years of compensation, the beta cells eventually die, resulting in diabetes 
(8).  Some individuals become obese and compensate with beta cell expansion but never progress 
to type 2 diabetes, indicating some environmental and/or epigenetic contribution to the disease 
(9).  Concomitant with beta cell loss in type 2 diabetes, there is support for beta cell dysfunction 
since islets from type 2 diabetic donors have impaired glucose-stimulated insulin secretion 
(GSIS) compared to normal donor islets but without a significant difference in islet insulin 
content (10, 11).  This notion drives research in the field toward therapeutics that may increase 
the function of these existing beta cells.  Other avenues of research are focused on preventing 
beta cell death, enhancing beta cell regeneration, or development of stem cell and islet 
transplantation therapies to replace lost beta cells (12-14).  Furthermore, many of the genes 
identified in human genome-wide association studies of diabetic individuals are directly 
associated with beta cell function, cementing the theory that beta cell dysfunction is central to the 
development of type 2 diabetes (15, 16). 
 
1.2 THE PANCREATIC ISLET 
 
Pancreatic islets of Langerhans, first described by Paul Langerhans in 1869, are small 
clusters of multiple endocrine cell types that comprise about 1-2% of the pancreas by mass (3, 
17). Pancreatic islets consist of at least 4 major cell types: insulin secreting beta cells, glucagon 
secreting alpha cells, somatostatin secreting delta cells, and pancreatic polypeptide secreting PP 
cells (18).  The architecture or human islets is such that alpha and beta cells are mixed throughout 
the islet (19).  Recently, it was discovered in human islets that alpha cells are adjacent to blood 
vessels while beta cells are more interior and, due to the invaginations of epithelium unique to 
human islets there are greater numbers of alpha cells in the core of the islet (20).  These new 
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findings suggest rodent islets are actually similar to human islets.  Since rodent islets contain a 
core of beta cells with alpha cells near the periphery, perhaps the difference in overall cell 
organization is merely due to the vasculature.  An islet can contain from a few to 5000 cells with 
beta cells making up at least two-thirds of the islet (3).  Each beta cell contains ~10,000 granules 
with about 5% of these granules pre-docked at the plasma membrane and about 20% within 300 
nm (roughly one granule diameter) from the plasma membrane (21, 22).  The large amount of 
insulin granules gives the beta cell the capacity to secrete insulin over long periods of time.  
Although the beta cell stores many granules, each with a half-life of ~3-5 days, newly synthesized 
granules can be secreted as early as 45 min after synthesis and are preferentially secreted over 
older granules (23-25).  
 
1.2.1 Biphasic Insulin Secretion from Pancreatic Islet Beta Cells 
In response to increased blood glucose, pancreatic islet beta cells secrete insulin in a 
biphasic manner (Figure 1-1).  Glucose enters the beta cell and is rapidly metabolized to yield a 
net increase in the ATP/ADP ratio.  As a result, ATP-sensitive potassium (KATP) channels close 
and cause membrane depolarization which opens voltage-dependent calcium channels (26). 
Subsequent calcium influx leads to insulin granule exocytosis (27-29).  This stimulus-secretion 
coupling pathway results in a rapid robust spike of insulin secretion called ‘first-phase’, derived 
from insulin granules pre-docked/juxtaposed within 100-200 nm of the plasma membrane, and 
referred to as the ‘readily releasable pool’ (RRP) (30, 31).  After the first-phase peak, the insulin 
release rate drops to 2 to 5 fold above basal secretion and is sustained at this lower rate of insulin 
release, called ‘second-phase’, which persists until euglycemia is restored (32). 
Second-phase insulin secretion thought to require the recruitment of granules from 
intracellular storage pools to the plasma membrane and involves reorganization of the 
filamentous actin (F-actin) cytoskeletal network (Figure 1-2A) (33-35).  Specifically, the 
reorganization takes place in the cortical F-actin web (Figure 1-2B).  In type 2 diabetes there is a 
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loss of both first and second phase insulin secretion (36). As insulin secretion can occur over the 
course of hours, the second phase can account for the majority of insulin released when compared 
to the first phase, although this does not discount the importance of the first phase in curtailing 
hepatic glucose output and glucagon secretion from alpha cells (37, 38).  There is far less known 
about the mechanistic regulation of second-phase insulin secretion.  Key proteins shown to be 
required or have a role in both phases of insulin secretion include the SNARE protein Syntaxin 4, 
the SNARE-related protein tomosyn-2, and granuphilin (39-41).  The SNARE protein Syntaxin 1 
is only required for first-phase (42).  The SNARE proteins will be described in detail in section 
1.7.  Currently identified regulators specific to second phase insulin secretion include, Cdc42, 
PAK1, and RhoGDI (43-45).  These will be discussed in detail in later sections. 
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Figure 1-1.  Biphasic glucose-stimulated insulin secretion from islet beta cells.  In response to a 
square-wave increase in glucose concentration, islet beta cells secrete about 50 granules in a first phase 
of secretion.  This phase is thought to be accounted for by the RRP granules depicted in the figure.  
When the glucose stimulus persists, beta cells secrete in a second phase that is a lower rate, sustained 
process that can continue for hours.  Second phase is thought to require the reserve pool granules to be 
recruited to the plasma membrane for secretion. 
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Figure 1-2.  F-actin regulates granule access to the readily releasable pool.  A)  Insulin granules are 
stored in an intracellular reserve pool behind a cortical web of F-actin (1).  Granules that are already 
present at or near (<50nm) the plasma membrane are considered the readily releasable pool (RRP).  
Upon glucose stimulation, this F-actin is remodeled to allow granules to translocate to the RRP for 
secretion.  B)  Cartoon showing difference between stress fibers and cortical F-actin just below the 
plasma membrane at the midplane of the beta cell.  Lower panels show confocal images of MIN6 cells 
either stained with FITC-Phalloidin (MIN6 cell cluster is shown, courtesy of Dr. Angela Nevins) or 
expressing a live-cell F-actin probe Lifeact-GFP (single cell is shown) to show F-actin localization. 
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1.2.2 The Triggering and Amplifying Pathways of Insulin Secretion 
Initially described 20 years ago by two different research groups, the triggering and 
amplifying pathways describe how glucose metabolism elicits insulin secretion (46, 47).  The 
ability of glucose to cause an increase in cytosolic [Ca
2+
] resulting in insulin secretion is referred 
to as the triggering pathway (2). The triggering pathway (sometimes referred to as the KATP-
dependent pathway) can be activated by other non-nutrient secretagogues such as KCl, which 
depolarizes the beta cell, causing calcium channels to open and insulin granules pre-docked at the 
PM to fuse an release their insulin cargo from the beta cell (48).  The triggering pathway is 
commonly associated with first-phase insulin secretion.  In addition to the triggering effect, 
glucose metabolism results in additional signals that enhance the amount of insulin secreted in 
response to the triggering pathway, termed the amplifying pathway (also referred to as the KATP-
independent pathway) (48).  It is important to note that the amplifying pathway requires the initial 
triggering pathway in order to manifest its effects on insulin secretion.  The amplifying pathway 
is commonly associated with second-phase insulin secretion, although there is evidence now that 
amplification has effects in both phases of insulin secretion (34, 49).  The triggering and 
amplifying pathways can be separated in vitro using a drug called diazoxide.  Diazoxide binds to 
the KATP channel holding it open even in the presence of elevated ATP levels (Figure 1-3A) (50).  
Under the diazoxide paradigm, while KATP channels are held open, depolarizing levels of KCl 
trigger calcium influx and insulin secretion.  Further addition of glucose elicits amplified insulin 
secretion and is termed the amplifying pathway (Figure 1-3B) (48).  Importantly, the amplifying 
pathway does not cause further elevation of cytosolic [Ca
2+
] (48).  Sulfonylurea drugs can also be 
used to demonstrate the amplifying pathway by binding to a regulatory subunit of the KATP 
channel to cause channel closure which induces membrane depolarization (2).  Use of either 
diazoxide or sulfonylurea essentially clamps the beta cell KATP channels so that they are not 
affected by glucose-induced elevations in ATP concentration, and so any changes in insulin 
secretion in response to glucose are independent of changes in cytosolic [Ca
2+
].  This model 
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system has proven key towards elucidating the factors and signaling events underlying this 
otherwise uncharacterized amplifying/second-phase secretory pathway. 
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Figure 1-3.  The triggering and amplifying pathways of insulin secretion.  A)  Upon entry into the 
beta cell through the Glut2 transporter, glucose is metabolized leading to increased ATP/ADP ratio 
which closes ATP-sensitive K
+
 channels (KATP) to cause membrane depolarization and Ca
2+
 influx 
through voltage-dependent calcium channels (VDCC).  This calcium influx stimulates the exocytosis of 
insulin which depends on the target-SNARE proteins Syntaxin 1/4 and SNAP-25 on the plasma 
membrane and the vesicle-SNARE protein VAMP2 on the insulin granule membrane.  These three 
SNARE proteins form a heterotrimeric complex that facilitates membrane fusion.  Glucose metabolism 
also signals through a metabolic amplifying pathway that increases the amount of insulin secreted in 
response to the triggering pathway, but without any further changes to Ca
2+
 influx.  Diazoxide holds the 
KATP channel open, preventing its closure in response to ATP/ADP ratio.  B)  Treatment with diazoxide 
and KCl elicits the triggering pathway depicted in (A) causing increased cytosolic Ca
2+
 ([Ca
2+
]c) and 
insulin secretion.  In the further presence of glucose, the amplifying pathway further enhances insulin 
secretion without increasing [Ca
2+
]c. Graphs shown are merely an illustrative example based on results 
from Henquin, et al. (2). 
 
11 
 
 While it is well accepted that triggering is the result of calcium influx, the exact 
mechanism behind the amplifying pathway is unclear, although it is apparently dependent on 
glucose metabolism (47).  It has been shown that all metabolized nutrients can activate the 
amplifying pathway, but the second messenger downstream of glucose has remained elusive (2).  
The search for the mediator(s) of the amplifying pathway has been the focus of much research 
and certain molecules have evidence both for and against a role, such as inositol phosphates, 
protein kinase C (51), the ATP/ADP (52, 53) and GTP/GDP (54) ratios, and glutamate (55).  
Candidates with overall supporting evidence for a role in metabolic amplification include protein 
acylation (via acyl-CoA) (56-58) and mitochondrial citrate production (59).  Reduction of 
mitochondrial cytochrome C also increases in response to metabolism and increased [Ca
2+
]c (60).  
Finally, NADPH has the potential to be a metabolic coupler (61), although NADPH alone cannot 
account for the amplifying pathway as NADPH requires the presence of cAMP and ATP to have 
its effects.  Although it is clear that mitochondrial and metabolic signals in the beta cell play an 
important and complex role in the amplifying pathway [reviewed in (62)], much investigation still 
remains to fully understand this process. 
Cytoskeletal dynamics have recently begun to be investigated for roles in glucose-
induced amplification of insulin secretion.  The diazoxide paradigm was used in islets in 
conjunction with pharmacological disruption of F-actin using latrunculin or stabilization of F-
actin using jasplakinolide (34).  It may seem contradictory, but either polymerization or 
depolymerization of F-actin using these drugs elicited potentiation of biphasic insulin secretion, 
consistent with much of the published literature (34).  This study highlights how F-actin 
remodeling may fine-tune and regulate the amount of insulin that is secreted in response the 
triggering and amplifying mechanisms.  Since stabilization of F-actin would be expected to 
prevent secretion, one explanation for the opposite result may be due to the drug jasplakinolide.  
Jasplakinolide stabilizes F-actin in vitro, but in vivo it can also disrupt F-actin and nucleate actin 
polymerization (63), which may account for its potentiating effects.  Two other caveats to the use 
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of such reagents complicates determination of the role of F-actin in beta cells: 1) the need to pre-
treat for a minimum of 20 min, which, in the case of latrunculin, shifts granule distribution to the 
plasma membrane prior to stimulation (64), and 2) the induction of global changes to F-actin by 
altering the F/G-actin ratio, as opposed to the localized alterations that occur in response to 
glucose in beta cells (33, 65).  As such, it is important to study beta cells using reagents that act 
specifically upon key regulators of F-actin dynamics as opposed to the entire F-actin structure in 
order to elucidate more nuanced regulatory roles of localized cytoskeletal dynamics. 
 
1.3 SMALL RHO FAMILY GTPASES AND REGULATION OF INSULIN SECRETION 
 
 Small GTPases (guanosine nucleotide triphosphatases) play many roles in cell biology 
including, but not limited to cytoskeletal reorganization, vesicle trafficking, and cell growth (66).  
These GTPases are known as the Ras superfamily due to their sequence homology.  The best 
studied members of this family include Ras, Rho, Rab, Arf, Rap and Ran (67).  Specifically of 
importance to F-actin remodeling is the Rho family, which contains Rho, Rac, and Cdc42. Small 
GTPases become activated when bound to GTP and remain active until the GTP is hydrolyzed to 
yield GDP and inorganic phosphate (66).  This cycle of GTP binding and hydrolysis is regulated 
by guanine nucleotide exchange factors (GEFs) which promote the dissociation of GDP and 
binding of GTP, GTPase activating proteins (GAPs) which stimulate GTP hydrolysis, and GDP 
dissociation inhibitors (GDIs) which prevent GDP dissociation (68).  Once in the activated GTP-
bound state, small GTPases will bind to effector molecules to propagate their signal.  In 
pancreatic beta cells, Cdc42 leads to Rac1 activation through p21-activated kinase (PAK1) (43). 
The third member of the Rho family, RhoA, was initially suggested against having a role in 
insulin secretion (69), although more recently RhoA was implicated as a negative regulator of 
insulin secretion (70).  The following subsections will describe the Cdc42-PAK1-Rac1 pathway 
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as it is known to function in beta cells, followed by sections with emphasis on PAK1 and its 
substrates, Rac1, and finally a discussion of other GTPases with relevance to the beta cell. 
 
1.3.1 The Cdc42-PAK1-Rac1 Signaling Pathway 
Using beta cell specific Cdc42 knockout mice, Cdc42 was found to be required for cell 
polarization responsible for microlumen formation, which is needed for final pancreatic 
architecture (71).  As such, studies focusing upon the role of Cdc42 signaling as it pertains to 
GSIS in pancreatic beta cells have instead used siRNA-mediated Cdc42 depletion, a more acute 
method of depletion which avoids developmental artifacts, to determine that Cdc42 in both 
human and rodent islets is required for specifically for the second phase of insulin secretion (43, 
45).  More recently, a screen for small molecule inhibitors specific for Cdc42 yielded the 
compound ML-141 (72).  ML-141 is a selective reversibly non-competitive inhibitor of Cdc42.  
While the ML-141 inhibitor has shown the ability to prevent EGF-stimulated Cdc42 activation in 
fibroblast cells, the effects in beta cells have yet to be investigated (72). 
Cdc42 and Rac1 activation can be measured by a pull down assay using the Cdc42/Rac1 
interactive binding domain of PAK1 which specifically binds to GTP-bound Cdc42 and Rac1 
(73).  In mouse insulinoma MIN6 and rat insulinoma INS 832/13 beta cell lines, Cdc42 is 
activated within 3 minutes of glucose stimulation and activation declines to basal levels within 
the following 2 minutes (43, 65, 74, 75).  This activation coincides with post-translational 
modifications like O-glycosylation, carboxymethylation and prenylation (65, 76).  Depletion of 
Cdc42 from either mouse or human isolated pancreatic islets causes a selective loss of second-
phase insulin secretion (43, 45).  The actual signaling factor that causes Cdc42 activation 
specifically in response to glucose and how this controls second-phase is not yet clear, although it 
is known that the signal requires glucose metabolism since non-metabolizable glucose analogues 
or KCl-depolarization induced Ca
2+
 influx fail to induce Cdc42 activation (43).  Recent findings 
suggest a role for the GEF Cool-1/βPix in mediating Cdc42 activation (74).  Within 2 min of 
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glucose stimulation, the association between Cdc42 and βPix increases by ~3-fold compared to 
unstimulated conditions (74).  This binding event immediately precedes Cdc42 activation at 3 
min, consistent with a role for βPix as a Cdc42 GEF.  siRNA-mediated depletion of βPix ablates 
glucose-induced Cdc42 activation and decreases glucose-stimulated insulin secretion (74), 
although the upstream activator of βPix is unknown.  Activated Cdc42 directly binds to PAK1, 
which then becomes activated through autophosphorylation on Thr 423 after 5-10 min of glucose 
stimulation (43, 73).  Islets from PAK1 knockout mice exhibit drastically reduced second-phase 
GSIS, placing PAK1 downstream of Cdc42 in the regulation of second-phase insulin secretion 
(43, 45).  PAK1 activation is required for Rac1 activation, and Rac1 is activated after 15-20 min 
of glucose stimulation (43). 
Under unstimulated conditions, both Cdc42 (44, 65, 77) and Rac1 (78) are maintained at 
a low level of activation via sequestration by GDIs.  Two GDIs have been identified in beta cells 
that regulate Cdc42: Caveolin-1 (77) and RhoGDI (44).  The subcellular distribution of Cdc42 
impacts its activation since its regulatory GDIs are also differentially localized to cytosol and 
plasma membrane.  Under unstimulated conditions the majority of Cdc42 resides in the cytosol, 
and the remainder is located at the plasma membrane and secretory granule membrane (74, 77).  
Inactive Rac1 is localized mainly in the cytosol (79).  Caveolin-1 is a membrane bound protein 
important for forming caveolae in many cell types, but also has a major role in signal transduction 
(80-82).  Caveolin-1 has been found to function as a GDI for Cdc42 in several cell types, 
including islet beta cells (77, 83).  Evidence for this GDI role for Caveolin-1 in beta cells stems 
from studies showing that Caveolin-1 associates specifically with Cdc42 on the insulin granule 
membrane (77).  When Caveolin-1 levels are depleted in islet beta cells, Cdc42 is aberrantly 
activated and basal insulin secretion inappropriately increases by 2-fold (77).  The other identified 
GDI, RhoGDI, is cytosolic and acts as a GDI for Cdc42 (44) and Rac1(79) in beta cells. 
RhoGDI was found to interact with the cytosolic pools of Cdc42 and Rac1 in MIN6 beta 
cells, but regulates them differently depending on the duration of glucose stimulation (44, 79).  
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For example, RhoGDI becomes phosphorylated on tyrosine 156 within 3 min of glucose 
stimulation to dissociate from Cdc42 but not Rac1 (44).  After 10-20 min of glucose stimulation, 
RhoGDI becomes phosphorylated on serines 101 and 174 and dissociates from Rac1 (44).  In 
bovine brain, the serine phosphorylation sites on RhoGDI were identified as PAK1 target sites, 
which fit well in the model where PAK1 is required for Rac1-RhoGDI dissociation (44, 84).  
Furthermore, the dissociation of RhoGDI from Rac1 occurs only in response to the amplifying 
pathway, but not the triggering pathway, supportive of a glucose-dependent regulation of 
RhoGDI-Rac1 complexes (44).  Mutation of tyrosine 156 to phenylalanine blocked glucose-
induced Cdc42 dissociation and similarly, mutation of serines 101 and 174 to alanine blocked 
Rac1 dissociation (44).  It is likely that serines 101 and 174 are phosphorylated on RhoGDI in 
response to the amplifying pathway, thus conferring glucose-specific Rac1 dissociation, although 
this has yet to be tested directly (44).  Nevertheless,  MIN6 or INS-1 cells,  and mouse islets 
depleted of RhoGDI all showed a robust potentiation of GSIS, specifically in the second phase in 
islets, consistent with a selective role for RhoGDI in the amplifying pathway (44, 79).  The 
enhanced secretion was correlated with potentiated Cdc42 activation, which presumably enhances 
PAK1 and Rac1 activation, although these events have not yet been investigated under RhoGDI 
depletion in beta cells (44). 
Currently, there are few characterized downstream targets of Cdc42 in the beta cell.  In 
addition to PAK1 activation, Cdc42 may activate N-WASP and the Arp2/3 complex in beta cells 
to cause glucose-stimulated insulin secretion and actin remodeling (85).  Cdc42 also binds to the 
v-SNARE VAMP2 on the insulin granule via a direct interaction, regardless of GTP- or GDP-
bound status (86).  After glucose stimulation, Cdc42 translocates to the plasma membrane where 
it is activated and may have a role in targeting granules to the plasma membrane for secretion, 
since Cdc42, VAMP2 and Syntaxin 1A can all participate in a complex (86).  The reason(s) that 
Cdc42 activation is required specifically for second-phase glucose-stimulated insulin secretion is 
not completely clear.  Cdc42 is likely activated early (3 min after stimulation) in order to begin 
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signaling cascades, one of which is through PAK1, that either mobilize granules toward the 
plasma membrane for release, enhance the release competence of granules that are nearby the 
plasma membrane, or both. 
 
1.3.2 The Role of PAK1 Signaling in the Beta Cell 
 PAK1 belongs to a family of PAK isoforms that are grouped into two main categories 
based upon sequence homology; Group I PAKs include PAK1, PAK2, and PAK3, while Group II 
includes PAK4, PAK5, and PAK6.  PAK1 is the most studied family member.  It is important to 
point out that the 21 kDa proteins that activate PAK1 are the small Rho GTPases Rac and Cdc42, 
not the cyclin-dependent kinase inhibitor p21.  Depending on the cell type, either Cdc42 or Rac1 
are able to interact with the Cdc42/Rac1 interactive binding domain of PAK1, which in turn 
induces a conformational change where the regulatory domain of PAK1 dissociates from the 
kinase domain, triggering PAK1 activation (73).  In beta cells, Cdc42 activates PAK1, and PAK1 
is necessary for Rac1 activation (43).  Recently, PAK1 levels were observed to be decreased in 
islets from type 2 diabetic humans, and human islets treated with the PAK1 inhibitor IPA3 
showed attenuated second phase insulin release (45).  This study solidified the importance of 
PAK1 in human type 2 diabetes, specifically in pancreatic islet beta cells.  Moreover, mouse islets 
lacking PAK1 (from PAK1 knockout mice) also exhibited reduced second-phase glucose-
stimulated insulin secretion (45).  Islets from PAK1 knockout mice showed defective glucose-
induced ERK activation in beta cells (45).  PAK1 could be regulating ERK activation through 
multiple mechanisms including PAK1 activation of Raf and/or MEK and Raf/MEK/ERK binding 
to PAK1 as a signaling scaffold (87, 88).  In addition to signaling through ERK,  PAK1 in other 
cell types has been demonstrated to utilize several other substrates for phosphorylation, including 
LIM kinase (89), Filamin A (90), myosin light-chain kinase (MLCK) (91), RhoGDI (84), MEK 
(87, 92), and the p41-Arc subunit of the Arp2/3 complex (93).  As such, it remains possible that 
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the modification of one or more of these targets by PAK1 could contribute to second-phase 
insulin secretion. 
 
1.3.3 The Role of Rac1 Signaling in the Beta Cell 
Rac1 activation occurs within 15-20 min of glucose stimulation and has been shown to be 
required for glucose-stimulated insulin secretion (69, 78, 94).  In the rat beta cell line INS-1, 
expression of dominant negative Rac1 (T17N-Rac1) blunted glucose- and forskolin plus glucose- 
induced secretion, but had no effect on KCl-induced secretion, demonstrating the glucose-
specificity of Rac1 (78).  Subsequently, a study using inhibitors against Raf-1 and 
farnesyltransferase or using knockdown of ERK showed that these proteins are important for 
glucose-induced Rac1 activation in the rat beta cell line INS 832/13 (95).  Since Rac1 is activated 
after second phase has already begun, it might be that Rac1 is not required for the initiation of 
second phase, but may play a role in sustaining secretion.  Potential effectors that Rac1 acts 
through to mediate glucose-stimulated insulin secretion include Gelsolin (96) and the protein 
complex Nox (97).  Rac1-dependent PIP2 production was suggested to be a driving force to 
inactivate Gelsolin and sequester it at the PM (98).  In this manner, F-actin could be severed, then 
re-polymerized, and severed again based on the cycling of Rac1 GTP/GDP loading (98).  The 
Nox complex is responsible for superoxide production and the complex assembly depends on 
Rac1 activation (76).  Inhibition of the Nox complex led to decreased glucose-stimulated insulin 
secretion, therefore Nox is believed to be a positive effector of insulin secretion downstream of 
Rac1 (97). 
 
1.3.4 Other Small GTPases 
Multiple other small GTPases have been investigated for their roles in vesicle trafficking, 
cytoskeletal dynamics and exocytosis.  This section will briefly highlight candidates for 
regulation of biphasic insulin secretion from islets, including Arf6, RhoA, Rap1, Rab, and RalA.  
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The small GTPase Arf6 was recently reported to become activated within the first minute of 
glucose stimulation and was proposed to be an upstream activator of the Cdc42 pathway (75).  
However, Arf6 was affiliated with both glucose and KCl-stimulated insulin secretion (75), and 
not solely glucose stimulated as would have been consistent with the responsiveness of Cdc42 
(43).  While Cdc42 and Rac1 are positive regulators of secretion in beta cells, the role of the other 
major Rho family GTPase, RhoA, has remained unclear, given that conflicting reports argue its 
role as both a positive and a negative regulator of secretion in beta cells (70, 99).  Rap1 has also 
been shown to function as a positive regulator of insulin secretion.  Rap1 is activated downstream 
of GLP-1 signaling in beta cells due to cAMP-dependent activation of the Rap1 GEF Epac2 (100, 
101).  Rap1 is required for the full potentiation of glucose-induced insulin secretion by cAMP 
(100) and also has a role in beta cell proliferation through the mTOR pathway (102). 
Finally, RalA and the Rabs have recently been shown to be important in insulin secretion 
and may have ties to the Cdc42 pathway and F-actin remodeling, respectively.  RalA is a member 
of the Ras-family GTPases and is thought to have roles in exocytotic processes (103).  In mouse 
islets, depletion of RalA results in reduced first and second phase of insulin secretion, while 
overexpression of RalA in MIN6 cells enhances insulin secretion (104).  The mechanism of RalA 
action involves its activation by the Ral GEF RalGDS and signaling through Arf6 and 
phospholipase D1, although the connection of RalA to Arf6 has yet to be investigated in beta 
cells (105).  In the case of the Rabs, although many have roles in membrane trafficking, Rab27a 
and Rab3a are of particular interest for insulin secretion.  Rab3a is important for the size of the 
readily releasable pool of granules, while Rab27a is important for refilling the releasable pool 
(106).  This could be explained by Rab27a signaling downstream to myosin Va to promote 
insulin granule transport to the plasma membrane, linking this Rab to the F-actin cytoskeleton 
(107, 108).  
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1.4 F-ACTIN AS A REGULATOR OF EXOCYTOSIS 
 
F-actin has been recognized as a regulator of exocytosis for more than 40 years (1, 109-
112).  Use of F-actin disrupting drugs like cytochalasins, latrunculins, clostridium C2 toxins, and 
F-actin polymerizing drugs like phallotoxins and jasplakinolide have proven useful in delineating 
F-actin’s role(s) in secretory/exocytotic processes across multiple cell types (1, 65, 112).  These 
cell types include beta cells and acinar cells (113), chromaffin and PC12 cells (114, 115), 
melanotrophs and lactotropes (116, 117), neutrophils (98, 99, 118), platelets (119), endothelial 
cells (120), neurons (121), adipocytes (122), and myocytes (123).  Landmark work by Orci, et al. 
showed electron micrographs of islet beta cells depicting F-actin in the form of a meshwork 
barrier just beneath the plasma membrane and in the form of tracks on which granules could 
translocate to the PM (1).  Aside from beta cells, most research on F-actin in secretion has been 
conducted in cultured adrenal chromaffin cells and PC12 cells.  In chromaffin cells, F-actin also 
forms a cortical ring beneath the plasma membrane and colocalizes with cytoskeletal proteins like 
myosin, caldesmon (109, 124, 125) Gelsolin and Scinderin (126), and fodrin (127). 
 
1.4.1 Positive and Negative Roles of F-actin in Secretion 
To sustain insulin release, mature insulin granules in intracellular storage pools must be 
mobilized toward the plasma membrane.  This process coincides with glucose-induced 
remodeling of the actin cytoskeleton (33, 65, 128).  In this sense, F-actin ‘remodeling’ in beta 
cells encompasses the simultaneous localized depolymerization and polymerization of F-actin 
across the cell in a concerted manner, such that the F/G-actin ratio does not change in response to 
glucose (65).  F-actin was long thought to function solely as a barrier to regulate insulin granule 
accumulation at the plasma membrane (1, 109), such that its depolymerization results in more 
morphologically docked granules and may confer enhanced release competence to granules (34, 
64).  Even though drug treatment studies suggest that F-actin is simply a blockade against 
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secretion, evidence of positive effects of the cytoskeleton in stimulus-induced insulin secretion 
exists as well (129-132).  Glucose has been shown to increase F-actin in some cases and decrease 
F-actin in others (130, 131, 133). 
 
 1.4.2 F-actin, Beta Cell-Cell Contacts, and the Regulation of Basal Insulin Secretion 
Control of basal insulin secretion, the amount of insulin secreted under non-stimulatory 
or sub-threshold conditions, is a critical part of physiology (134).  Dysregulation of basal insulin 
secretion occurs in type 2 diabetes (134) and also in certain genetic disorders where the KATP 
channel is mutated (135).  Aberrantly increased insulin secretion under normal blood glucose 
conditions can cause hypoglycemia acutely, but over time may contribute to insulin resistance in 
the peripheral tissues (134).  The cell’s ability to keep basal insulin secretion at a normal low 
level seems to be linked to the F-actin cytoskeleton and cell-cell communication. 
Recently, the actin cytoskeleton has been linked to roles in basal exocytosis through 
control by several factors: βPix (74), Cav-1 (77), focal adhesion kinase (FAK) (136) and EphA-
Ephrin-A signaling (132).  Depletion from beta cells of either βPix or Cav-1, which are both 
regulators of Cdc42 activation, leads to dysregulated basal insulin secretion (74, 77).  
Pharmacological inhibition of FAK caused an increase in basal insulin secretion which was 
related to disrupted beta cell F-actin structure due to discontinuous cell-cell contact (136, 137).  
EphA5-Ephrin-A5 signaling mediates a paracrine signaling pathway that regulates insulin 
secretion.  Decreased cell-cell contact in beta cells decreases EphA5 phosphorylation levels, 
which leads to increased basal secretion (132).  The EphA5-Ephrin-A5 signaling mechanism 
seems to be required for normal beta cell function as knockout of Ephrin-A5 in mice largely 
inhibited glucose-stimulated insulin secretion and caused whole-body glucose intolerance (132).  
Other forms of cell-cell contact, such as gap junctions formed by connexin 36, have been 
implicated in basal insulin secretion (138-141).  In islets isolated from connexin 36 knockout 
mice, basal insulin secretion was increased (147).  In another study, under high-fat diet 
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conditions, mice lose protein levels of connexin 36, leading to increased basal secretion, 
suggesting this may be a potential effect in human obesity and type 2 diabetes disease progression 
(138).  Taking these findings together, there is a crucial link between F-actin cytoskeletal 
regulation, cell-cell contact, and control of basal and stimulated insulin secretion. 
A body of work suggests that maintenance of Cdc42 in its inactive state is important to 
maintain the normally low basal insulin secretion.  For example, siRNA-mediated knockdown of 
the Cdc42 GEF βPix in beta cells reduced both basal and glucose-stimulated insulin secretion and 
prevented glucose-stimulated Cdc42 activation (74).  Furthermore, knockdown of the GDI 
Caveolin-1 in both MIN6 cells and mouse islets caused a significant increase in basal insulin 
secretion, demonstrating that control of Cdc42 activation is important for keeping basal secretion 
in check (77).  It may be germane to point out that while Cdc42 has roles in both basal insulin 
secretion and second-phase GSIS, it is not clear whether these two functions lie within the same 
signaling pathway or are distinct from one another. 
 
1.5 ACTIN-BINDING PROTEINS IN EXOCYTOSIS AND GRANULE TRAFFICKING 
 
Glucose elicits F-actin remodeling in beta cells, while stimulation using KCl does not 
(65). Consistent with this, Cdc42 is activated by glucose to signal to downstream targets PAK1 
and Rac1, leading to second-phase insulin secretion (43, 44).  Since F-actin may also be 
necessary to inhibit insulin secretion under low glucose conditions (130), a dynamic role for F-
actin in corralling insulin granules via glucose-stimulated remodeling has been proposed (35).  In 
this sense, the role of F-actin may be as a barrier under unstimulated conditions, but become a 
facilitator of insulin secretion during glucose stimulation.  Since insulin granules are known to 
interact with F-actin filaments (142), this could be one way granules are mobilized to the plasma 
membrane in a regulated manner.  As previously discussed, F-actin remodeling is known to 
couple granule mobilization to the SNARE exocytosis machinery (33, 64, 86, 143).  Therefore, it 
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is pertinent to analyze proteins that control the polymerization and/or depolymerization of F-actin 
structures and where and when these events occur.  The idea that F-actin severing and stabilizing 
proteins may underlie glucose-stimulated F-actin remodeling fits with the current model and also 
leaves room for the potential modifiers of F-actin dynamics in the beta cell. 
 
1.5.1 F-actin Severing Proteins 
Glucose-induced F-actin remodeling inherently must involve regulated depolymerization 
of F-actin.  The best studied F-actin severing proteins that may play a role in this process include 
Cofilin, Gelsolin, and Scinderin.  Cofilin’s F-actin severing activity is regulated through 
phosphorylation on Ser 3 by LIM kinase which inhibits Cofilin, and dephosphorylation by the 
phosphatase Slingshot which activates Cofilin (144).  Cofilin is usually thought to be regulated 
upstream by PAK1 activation of LIM kinase, but recent findings suggest that in the beta cell 
PAK1 is dispensable for the phosphorylation state of Cofilin (45).  This is in contrast to skeletal 
muscle where PAK1 was required for the dephosphorylation of Cofilin phosphorylation (45).  
Whether Cofilin or its phosphorylation plays any role in GSIS remains to be investigated. 
Gelsolin is the founder of a family of calcium-activated actin-severing and capping 
proteins, first cloned in 1979 (145, 146).  This protein family includes Gelsolin, Scinderin, CapG, 
and many others (146), although only Gelsolin and Scinderin are known to be expressed in beta 
cells.  Gelsolin consists of 6 globular domains (S1-6), each of which binds calcium; S2 binds 
phosphoinositides (146).  Since its discovery, Gelsolin has been implicated in different aspects of 
cell biology including roles in cancer, binding to androgen receptor, and F-actin remodeling 
(147).  There are two isoforms of Gelsolin encoded as different mRNAs from the same gene: a 
cytosolic isoform and a secreted plasma isoform which contains a 50 residue N-terminal 
extension (148, 149).  Plasma Gelsolin in the blood is thought to be important for reducing 
inflammation after tissue injury and in recovery from certain infections (150), although the 
mechanisms of these functions are not well understood.  The larger portion of Gelsolin literature 
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relates to its cytosolic form and its role in F-actin remodeling.  Gelsolin is ubiquitously expressed 
and has been implicated in insulin secretion from beta cells (96, 151), but the affected phases of 
secretion and its mechanistic role in insulin secretion remains largely unstudied (96, 152-154). 
Scinderin shares nearly 60% sequence identity to Gelsolin (155).  Unlike Gelsolin, 
Scinderin expression is largely restricted to neuroendocrine, intestinal, and kidney tissue (154, 
156).  Despite their structural similarity, Gelsolin and Scinderin are differentially regulated by 
calcium and Scinderin plays a larger role in secretion from chromaffin cells (126, 157, 158).  
Scinderin becomes activated at lower levels of calcium (0.5µM Ca
2+
) than Gelsolin (~1-3µM 
Ca
2+
) (158).  In patch-clamped primary beta cells, peptides derived from Scinderin’s PIP2 binding 
domain were shown to inhibit calcium- or GTPγS-induced insulin secretion, potentially 
implicating Scinderin in glucose-stimulated insulin secretion (159). 
 
1.5.2 F-actin Stabilizing Proteins 
The two major F-actin stabilizing proteins which may have potential roles in beta cell F-
actin remodeling are α-Fodrin and Filamin A.  α-Fodrin, also known as spectrin, cross-links F-
actin under low calcium and releases actin upon calcium influx in chromaffin cells (127). α-
Fodrin also binds to Syntaxin 4 in vitro and in rat adipocytes (160, 161), which implicates it in the 
modulation of SNARE complex formation and may link this complexation to F-actin.  α-Fodrin 
can be cleaved by calpain and increased cleaved α-Fodrin is found in islet beta cells from type 2 
diabetic donors, suggesting compromised cellular cytoskeletal structure (162).  Filamin A is the 
most potent F-actin cross-linking protein identified and interacts with Cdc42, PAK1 and Rac1, all 
of which are vital for second-phase insulin secretion (43, 163-165).  PAK1 is known to 
phosphorylate Filamin A in vivo and in vitro, regulating its F-actin cross-linking activity (90), 
although this has yet to be shown in beta cells.  
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1.5.3 F-actin Associated Proteins 
In addition to F-actin severing and stabilizing proteins, there is a set of proteins that have 
the potential to play critical roles in insulin secretion that should be discussed; these include 
Arp2/3, Myosin light-chain kinase (MLCK) and Myosin Light-Chain 2 (MLC2), and FAK.  The 
Arp2/3 complex has direct links to Cdc42 signaling in other cell types and could therefore be 
involved in glucose-induced F-actin remodeling.  Arp2/3 has been implicated in secretion from 
neuroendocrine cells (114), and recently was suggested to play a critical role in glucose-
stimulated insulin secretion, potentially in second phase through interaction with Cdc42 (85). 
MLCK and MLC2 are implicated in glucose-stimulated insulin secretion and hold the 
potential for effects on F-actin remodeling and granule mobilization.  Myosin IIA is the most 
studied non-muscle myosin and is involved in F-actin remodeling and exocytosis (166, 167).  
Myosin IIA is comprised of two identical heavy chains coiled together by a long tail domain each 
with a myosin head domain, two essential light chains, and two regulatory light chains (Figure 1-
4A).  The regulatory light chain is referred to as myosin light chain 2 (MLC2) and is 
phosphorylated by MLCK (Figure 1-4B); an event implicated in insulin secretion (168).  In 
support of this, an increase in MLC2 phosphorylation on Ser 19 was observed in beta cells (169).  
Phosphorylation of MLC2 Ser 19 increases the ATPase activity of Myosin IIA (170).  Ca
2+
-
calmodulin directly activates MLCK, and ERK has been shown to phosphorylate and increase the 
sensitivity of MLCK to Ca
2+
-calmodulin (171).  MLCK activity is increased by glucose in beta 
cells, suggesting a potential link between ERK and MLCK in glucose-stimulated insulin secretion 
(168).  PAK1 has also been shown to phosphorylate MLCK, but has an inhibitory effect on 
MLCK (91).  In addition to Myosin IIa, Myosin Va has been investigated in beta cells (128).  
Myosin Va was shown to be a positive regulator of granule localization to the plasma membrane 
and subsequent insulin secretion (128). 
Finally, FAK regulation of focal adhesion remodeling has implications for indirect 
regulation of F-actin remodeling and insulin secretion.  In MIN6 beta cells, FAK inhibition was 
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shown to prevent glucose-stimulated F-actin remodeling (137) and led to increased basal 
secretion and decreased GSIS (136).  Recently, islets of beta cell-specific FAK knockout mice 
were found to exhibit decreased ERK activation, reduced number of docked insulin granules that 
correlated with deficient insulin secretion, and impaired glucose induced cortical F-actin 
reorganization (172).  Thus, FAK likely acts in coordination with F-actin remodeling in order to 
regulate glucose-stimulated insulin secretion, but its linkage to Cdc42 and PAK1 remains 
unknown. 
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Figure 1-4.  Structure of myosin IIA and signaling.  A) Depiction of the structure of Myosin IIA.  B) 
Schematic of myosin light chain 2 (MLC2) regulation by different signaling pathways. 
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1.6 ROLE OF ERK IN ACTIN REMODELING AND SECRETION 
 
1.6.1 The Ras-Raf-MEK-ERK Pathway in the Beta Cell 
 Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated protein 
kinase (MAPK) family that functions in cell growth and survival, embryogenesis, and 
differentiation across many cell types (173).  The pathway leading to ERK activation in the beta 
cell involves various signals including Ca
2+
 influx and cAMP production.  In the beta cell, cAMP 
leads to activation of the small GTPase Rap1a which can activate B-Raf (174).  Raf then 
phosphorylates the MAP/ERK kinase (MEK) which subsequently phosphorylates ERK (Figure 1-
5) (173).  PAK1 can feed into this pathway as well by phosphorylating both Raf-1 and MEK1 to 
promote activation of each protein (87, 175, 176).  The involvement of Rap1a implicated the 
cAMP-responsive GEF Epac2 in B-Raf signaling and this pathway has recently been 
demonstrated in GLP-1 stimulated human islets (177). 
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Figure 1-5.  The Cdc42-PAK1 and Ras-Raf pathways feed into MEK-ERK signaling.  In the beta 
cell, glucose activates Cdc42 by 3 min of stimulation which then leads to PAK1 activation by 5 min.  
Raf is activated by upstream signals in many cell types, while in beta cells glucose is thought to mainly 
activate B-Raf.  Active PAK1 can phosphorylate Raf and MEK to promote Raf-MEK signaling which 
culminates in ERK activation.  Active ERK can then target downstream gene transcription events and 
cytosolic targets. 
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More than 15 years ago, ERK was shown to be activated in response to glucose in beta 
cells (178, 179).  However, initial studies with first-generation inhibitors yielded data that 
suggested ERK activation was not necessary for acute insulin secretion (178, 179).  These initial 
studies concluded that active ERK translocated to the nucleus to exert effects upon transcription, 
although did also acknowledge that a larger proportion remained in the cytoplasm (178-180).  
More recent studies using lower concentrations of PD98059 (20 µM) in rat islets revealed a 
necessity for ERK in glucose-stimulated insulin secretion (180); RNAi-targeting of ERK resulted 
also in attenuated GSIS and Rac1 activation (95).  Recently, a new selective MEK inhibitor has 
been generated, PD0325901, that will be useful in reconciling the role of ERK in GSIS (181). 
As a result of the controversy surrounding a role for ERK activation in GSIS, the effects 
of ERK activation in pancreatic beta cells on F-actin dynamics/signaling and granule 
translocation to SNARE sites have been relatively understudied.  In the case of ERK inhibition, 
use of high 100 μM doses of PD98059 were concluded to have no impact on glucose-induced F-
actin remodeling, although only stress fibers were analyzed, leaving the possibility of effects on 
cortical actin in the midplane of the cell (96).  Although it is clear that ERK has some connection 
to F-actin, since activate ERK localizes to the tips of F-actin processes in beta cells (96, 136).  
Depolymerization of F-actin using latrunculin seems to potentiate glucose-induced ERK 
activation, while stabilization of F-actin with jasplakinolide attenuates ERK activation, although 
the reason for this is unclear (96, 137).  It is interesting to note that both of these drugs can 
potentiate glucose-stimulated insulin secretion in beta cells, although it is unknown how ERK 
activation impacts secretion under either condition (34, 64, 65). 
 
1.6.2 ERK Targets Actin Regulatory Proteins 
ERK has been shown to phosphorylate synapsin I, cortactin, MLCK, FAK, and paxillin.  
Although synapsin I and II have now been suggested against having much role in glucose-
stimulated insulin secretion (182), the other F-actin-related ERK targets such as FAK and MLCK 
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have roles (168, 172); cortactin has yet to be investigated in beta cells (183, 184). ERK can also 
phosphorylate FAK and this disrupts FAK-paxillin binding (185-187).  Since FAK is required in 
beta cells for cortical F-actin dynamics, basal and stimulated insulin secretion, and focal adhesion 
remodeling (136, 137, 172), there exists potential for input from the ERK pathway through FAK 
signaling.  Additionally, MEK associates with paxillin and facilitates Raf-MEK-ERK signaling 
(188), and depletion of paxillin reduced glucose-stimulated insulin secretion and ERK activation 
in primary rat beta cells (136). 
 
1.7 SNARE-MEDIATED INSULIN EXOCYTOSIS 
 
Insulin exocytosis is mediated by a group of proteins termed soluble N-ethylmaleimide 
sensitive factor attachment receptor (SNARE) proteins.  The concept  SNARE proteins in 
regulated exocytosis was first elucidated in 1993 and rapidly confirmed by multiple groups and in 
many diverse cell types, including beta cells (189-194).  This mechanism is well-conserved from 
yeast to humans where SNARE proteins are required to facilitate the fusion of lipid bilayer 
membranes (192).  There are two main groups of SNARE proteins, target membrane t-SNAREs 
and vesicle-associated v-SNAREs.  In beta cells the t-SNAREs Syntaxin and synaptosomal-
associated protein of 25 kDa (SNAP-25, as well as its homolog SNAP-23) are localized to the 
plasma membrane whereas the v-SNARE VAMP2 (also known as synaptobrevin 2) is localized 
to the secretory vesicle (Figure 1-6).  Syntaxins have three N-terminal alpha helices denoted Ha, 
Hb, and Hc (Habc) followed by a linker domain and then the H3 SNARE helix domain that 
associates with the other SNARE proteins (192).  VAMP2 is a relatively small protein (~18 kDa) 
which mainly contains a single alpha-helical SNARE domain.  VAMP2 and Syntaxin each donate 
their one alpha-helix and SNAP-23/25 contributes two alpha-helices to form a coiled four helical 
heterotrimeric complex that brings the plasma membrane and vesicle membranes in close enough 
proximity for fusion (195).  The so-called ‘priming’ step involved in the SNARE complex 
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formation is ATP-dependent and the final initiation of regulated exocytosis requires calcium 
influx (21), although the exact mechanisms by which this calcium influx causes membrane fusion 
are not fully understood.  In addition, other priming factors are important for SNARE-mediated 
membrane fusion such as the Munc13 proteins and Doc2β, which also have calcium-binding 
activity that could aid in sensing increased cytosolic [Ca
2+
] (196). 
 
1.7.1 SNARE Requirement in Biphasic Insulin Secretion 
 In beta cells, the necessary SNARE isoforms are Syntaxin 1 and 4, SNAP-25 (and SNAP-
23), and vesicle-associated membrane protein 2 (VAMP2).  Indeed, the levels of multiple 
SNARE proteins are reduced in islets from type 2 diabetic donors for example Syntaxins 1 and 4, 
SNAP-25, and VAMP2, highlighting the functional importance of these proteins in the disease 
state (197).  In general, the Syntaxin 1 is required for first-phase insulin secretion only, while 
Syntaxin 4 is necessary for both phases of insulin secretion (39, 42).  The Syntaxins are regulated 
by a group of nSec1/Munc18 (SM) proteins.  The differential requirement of Syntaxin 1 versus 
Syntaxin 4 in biphasic secretion could be the result of SM protein regulation.  Syntaxin 1 and 
Syntaxin 4 are regulated by Munc18-1 and Munc18c, respectively, and these complexes are 
mutually exclusive (196, 198, 199).  Munc18-1 was recently discovered to be required for first-
phase insulin secretion, which is consistent with its role as a regulator of Syntaxin 1 (198).  
Munc18c is required specifically for second-phase insulin secretion (200), which may underlie 
Syntaxin 4’s role in second phase, but the mechanism of Syntaxin 4’s role in first-phase remains 
an open question.  It is hypothesized that upon stimulation, post-translational modification of SM 
proteins causes dissociation (in the case of Munc18c) or a binding mode shift (in the case of 
Munc18-1) to assist in the opening and binding of Syntaxin to its cognate v-SNARE VAMP2 
(Figure 1-6) (196).  Post-translational modification of the Syntaxin proteins also contributes to 
their activity, as glucose-induced production of nitric oxide causes S-nitrosylation of Syntaxin 4 
in beta cells, increasing Syntaxin 4 accessibility to VAMP2.  Another layer of regulation comes 
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from the protein Doc2β, which regulates Munc18-1 and Munc18c (196, 199, 201, 202).  Genetic 
ablation of Doc2β results in attenuated first- and second-phase insulin secretion (199).  Currently, 
the mechanism for how Doc2β regulates both phases is under investigation but likely has to do 
with its regulation of the Munc18 and the Munc13 proteins.  Recently, Munc13-4, part of the 
Munc13 family of priming factors, was shown to interact with the H3 SNARE domains of 
Syntaxins 1 and 4 in a calcium-dependent manner (203).  Since Munc13-4 interacts with Rab27a, 
a key protein regulating vesicle trafficking, this could underlie a mechanism linking GTPases to 
SNARE-mediated exocytosis (204). 
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Figure 1-6.  Regulation and mechanism of SNARE complex formation.  The SNARE complex 
forms first from the binding of Syntaxin 4 (Syn4) and SNAP-23/25 after stimulus induced release of 
Syn4 from Munc18c.  Phosphorylated Munc18c is bound by Doc2B.  VAMP2 can then bind to Syn4-
SNAP-23/25 complexes to form the SNARE complex and elicit membrane fusion. 
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 1.7.2 Linkage of F-actin Remodeling to SNARE-mediated Secretion 
 The SNARE proteins involved in insulin secretion are linked to F-actin by direct and 
indirect interactions.  These SNARE-F-actin interactions are thought to regulate SNARE protein 
function and influence insulin secretion (35).  Immunoprecipitation of Syntaxin 1, Syntaxin 4, 
and SNAP-25 from beta cells show co-precipitation of actin (33, 64, 137, 143, 205).  Of interest 
is the dynamic nature of the F-actin-SNARE interaction after glucose stimulation.  After 5-10 
minutes of glucose stimulation, F-actin dissociates from the Syntaxins and SNAP-25, but 
reassociates within 30 minutes after stimulation (33, 64, 137).  In the case of Syntaxin 4 this 
binding has been shown to be direct, while Syntaxin 1 seems to interact through an indirect 
mechanism (33, 64, 65).  Direct binding of F-actin to Syntaxin 4 was determined to occur at the 
N-terminus of Syntaxin 4, likely through the Hb helix while direct binding of F-actin to VAMP2 
was not detected in vitro (64).  The Syntaxin 4-F-actin interaction seems to be selective for 
Syntaxin 4, since all other SNAREs tested so far (Syntaxin 2 and 3, SNAP23, VAMP8) have not 
bound F-actin directly in vitro (119, 205).  In beta cells, evidence for Syntaxin 4 binding to F-
actin and not G-actin comes from treatment with the actin depolymerizing drug latrunculin, which 
abrogates the co-precipitation of actin with Syntaxin 4, showing that Syntaxin 4 will not bind to 
monomeric G-actin (64, 143).  Artificial disruption of Syntaxin 4-F-actin complexes in beta cells 
using a GFP-tagged truncation of Syntaxin 4 corresponding to the F-actin binding (Syntaxin 4 
residues 39-112) site led to increased secretion and increased VAMP-bound insulin granule 
accumulation at the cell surface, suggesting that F-actin binding to Syntaxin 4 played a role in 
limiting granule access to the PM (64).  Syntaxin 4 and 1 can also form heteromeric complexes 
with Cdc42 and VAMP2 in vitro, presenting a potential avenue for localized coupling SNARE 
proteins with Cdc42-mediated F-actin remodeling (86, 206). 
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1.8 RATIONALE AND CENTRAL HYPOTHESIS 
 
The rationale for the studies in this dissertation is that further understanding of the role 
for F-actin in regulating insulin secretion will not only help close a gap in understanding in the 
field of beta cell biology, but also uncover potential new therapeutic targets for diabetes treatment 
strategies.  The central hypothesis of this dissertation was formulated based on my preliminary 
data and the published literature described above regarding the known requirement for small Rho 
GTPases, SNARE proteins, and F-actin remodeling in in insulin secretion.  Thus, my central 
hypothesis is that, in the pancreatic beta cell, glucose signals through a Cdc42-PAK1-mediated 
pathway to remodel the F-actin cytoskeleton to mobilize insulin granules to SNARE docking sites 
at the PM to evoke glucose stimulated second phase insulin secretion.  To test this hypothesis, 
two main Aims were pursued: 1) Determine the role and requirement for PAK1 signaling in F-
actin remodeling, insulin granule mobilization, and SNARE docking at the PM in glucose-
stimulated insulin secretion, and 2) Investigate the role for the novel Syntaxin 4-interacting 
protein Gelsolin in regulating glucose-stimulated insulin secretion, F-actin remodeling, and 
Syntaxin 4-F-actin dynamics. 
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CHAPTER 2.  GLUCOSE MEDIATES EFFECTS ON CORTIAL F-ACTIN 
REMODELING AND AMPLIFICATION OF INSULIN SECRETION IN PANCREATIC 
BETA CELLS VIA PAK1-MEK-ERK SIGNALING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some of the text in this Chapter will be submitted for publication:  
 
Kalwat MA, Wang Z, Yoder SM, and Thurmond DC.  Glucose mediates effects on F-actin 
dynamics and the MAP kinase pathway in pancreatic beta cells via PAK1. 
 
Author Contributions: Wang Z generated data for figure 2-1A.  Yoder SM provided reagents for 
figure 2-1C.  The rest of the figures and text were generated by Kalwat MA.  
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2.1 INTRODUCTION 
 
 Insulin is secreted from pancreatic beta cells in a biphasic manner in response to fuel 
secretagogues.  A first phase peak in secretion occurs within 10 minutes after glucose stimulation.  
Following first phase, a lower-rate sustained second-phase secretion occurs that can persist for 
hours (55).  Biphasic insulin secretion occurs when glucose enters the beta cell through GLUT2 
glucose transporters and is metabolized leading to an increased ATP:ADP ratio (55).  This leads 
to the inhibition of ATP-sensitive K
+
 channels, causing membrane depolarization and calcium 
influx through voltage-sensitive calcium channels which results in insulin granule exocytosis (26-
29).  Both phases of insulin exocytosis are facilitated by SNARE proteins.  The target membrane-
SNAREs Syntaxin 1 and 4 and SNAP-25 reside at the plasma membrane while the vesicle-
SNARE VAMP2 is present on the insulin granule (194).  Syntaxin, SNAP-25, and VAMP2 form 
a heterotrimeric complex to facilitate insulin exocytosis.  Syntaxin 1 is only required for the first 
phase of secretion (42) while Syntaxin 4 is important for both phases (39), although the exact 
mechanisms by which  Syntaxin 4 participates in each of these phases of insulin secretion are not 
fully understood. 
 Glucose signaling and activation of the Cdc42-PAK1 pathway is required for second 
phase insulin secretion and may be a potential link to SNARE-regulated biphasic insulin secretion 
since Cdc42 can interact with VAMP2 (43, 45, 86).  Cdc42-PAK1 signaling has been elucidated 
as a key proximal step leading to second-phase glucose-stimulated insulin secretion since the 
depletion or inactivation of either of these proteins selectively impairs the second-phase (43, 45).  
Multiple studies have shown that upon entry of stimulatory levels of glucose into the beta cell, 
Cdc42 is activated within about 3 min (43, 65, 74, 85) , concurrent with the first phase release of 
insulin.  Following Cdc42 activation, PAK1 becomes phosphorylated and activated in a manner 
dependent on Cdc42 within 5-10 min more of glucose stimulation (43).  Concomitant with 
Cdc42-PAK1 pathway activation, glucose stimulates cortical F-actin remodeling after 5-10 
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minutes of stimulation (33, 65, 143, 172).  Cortical F-actin remodeling is characterized by a 
diminished F-actin intensity or breaking up of the cortical ring of F-actin (33).  By 20 min Rac1 
becomes activated and this is dependent on PAK1 activation (43).  Thus while Rac1 is a known 
actin remodeling factor, its activation would appear to occur too late to account for the 
initialization of F-actin remodeling induced by glucose stimulation.  Demonstrations of why 
regulated F-actin remodeling is important for secretion come from studies where F-actin is 
disrupted or stabilized pharmacologically in beta cells, leading to potentiated albeit dysregulated 
biphasic insulin secretion (33, 34).  Experimental F-actin disruption is normally done using the 
drug latrunculin which specifically binds to G-actin and sequesters it preventing polymerization 
(207).  Latrunculin treatment of beta cells causes the insulin granules to accumulate at the plasma 
membrane, but does not raise basal insulin secretion (64).  Upon stimulation with glucose, 
secretion is elevated many fold above normal and there is no distinction between first and second 
phase insulin secretion (33).  In the case of F-actin stabilization, the drug jasplakinolide is 
normally used, although care must be taken in data interpretation due to the effects of 
jasplakinolide.  Jasplakinolide causes the nucleation of new F-actin in addition to stabilizing the 
F-actin (207).  Since Jasplakinolide does not simply prevent the remodeling of the F-actin 
structure, this drug cannot answer the question about whether prevention of F-actin remodeling 
would prohibit insulin secretion.  The effects of latrunculin on beta cells suggest that F-actin may 
be a barrier under unstimulated conditions, and the similar effects of jasplakinolide suggest F-
actin may also have an active role in promoting exocytosis. 
In considering the molecular mechanism(s) by which glucose signals to initiate F-actin 
remodeling in beta cells, PAK1 emerges as a logical candidate to couple signaling to F-actin 
changes.  For example, PAK1 has multiple substrates with the potential to elicit changes in F-
actin structure, such as LIMK (89), Filamin A (90), p41-Arc (93), MLCK-MLC pathways (91), 
and the MAPK pathway through Raf/MEK (87, 92).  As a scaffold, PAK1 interacts with proteins 
such as the small GTPases Rac1 and Cdc42, as well as  the beta cell guanine nucleotide exchange 
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factor for Cdc42, βPix/Cool-1 (73).  PAK1 is implicated in type 2 diabetes, since islets from type 
2 diabetic individuals contain 80% less PAK1 protein than normal individuals (43).  Moreover, 
PAK1 is located in a region of chromosome 11 that is linked to type 2 diabetes disease risk (208, 
209), adding the potential for PAK1 gene variants to contribute to disease.  Therefore, 
determining how PAK1 functions in regulating insulin secretory processes in islet beta cells may 
provide insight into why defects in PAK1 are linked to diabetes or diabetic susceptibility.  Since 
our current understanding of both the regulation of second phase insulin secretion and glucose-
stimulated F-actin remodeling is incomplete, understanding how glucose mediates these 
processes is critical to the advancement of our knowledge of beta cell biology and to elucidate 
potential therapeutic avenues for diabetes.  From a broader perspective, since PAK1 is a 
ubiquitous protein, our results have relevance to other cell systems wherein PAK1 regulates 
secretory processes such as GLUT4 vesicle exocytosis in skeletal muscle (45). 
In this study we demonstrate the requirement of PAK1 signaling for normal glucose-
induced F-actin remodeling and implicate PAK1 in SNARE-mediated exocytosis.  Blocking 
PAK1 activation using the specific inhibitor IPA3 prevented normal glucose-induced F-actin 
remodeling.  IPA3 treatment also prevented the translocation of VAMP2-bound insulin granules 
to the plasma membrane.  In the beta cell, PAK1 was shown to signal through the MEK-ERK 
pathway in response to glucose to elicit cortical F-actin remodeling.  Interestingly, PAK1 
inhibition also resulted in altered Syntaxin 4-F-actin complexation.  Since Syntaxin 4-F-actin 
interactions are known to control insulin granule docking/fusion at the PM, disruption of this by 
IPA3 or PAK1 depletion may account for the selective attenuation of second phase insulin 
release.  These results support a model whereby glucose-stimulated Cdc42-PAK1-MEK/ERK 
signaling leads to F-actin remodeling, perhaps to direct insulin granule translocation to Syntaxin 4 
SNARE docking sites at the plasma membrane to support insulin secretion. 
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2.2 MATERIALS AND METHODS 
 
2.2.1 Materials, Reagents, and Plasmids 
Rhodamine-Phalloidin was from Life Technologies (Grand Island, NY).  Latrunculin B 
was from Calbiochem.  Rabbit anti-phospho-ERK1/2, mouse anti-ERK, rabbit anti-phospho-
MEK, rabbit anti-MEK, rabbit anti-PAK1, rabbit anti-phospho-Filamin A (Ser2152), and rabbit 
anti-Filamin A antibodies were from Cell Signaling Technology (Danvers, MA).  Diazoxide, 
IPA3, and rabbit anti-phospho-PAK1 (Thr423) were from Santa Cruz (Santa Cruz, CA).  Rabbit 
anti-actin was from Sigma (St. Louis, MO).  Two rabbit polyclonal anti-Syntaxin 4 antibodies 
were obtained for use in coimmunoprecipitation (Chemicon, Temecula, CA) and for 
immunoblotting (antibody described in (210)).  Mouse anti-SNAP-25 was from BD Biosciences 
(Mountain View, CA).  Mouse anti-VAMP2 was from Synaptic Systems (Germany).  Goat anti-
mouse horseradish peroxidase secondary antibody and PD0325901 were obtained from Thermo 
Fisher Scientific (Rockford, IL).  Goat anti-rabbit horseradish peroxidase secondary antibody and 
TransFectin lipid reagent were acquired from Bio-Rad (Hercules, CA).  ECL reagent and 
Supersignal Femto were purchased from GE Healthcare (Piscataway, NJ) and Pierce, 
respectively.  The rat insulin radioimmunoassay kits were obtained from Millipore (Billerica, 
MA).  The Lifeact-GFP plasmid was kindly provided by Dr. Louis Philippson and was generated 
as described (211).  The F/G Actin ratio kit was obtained from Cytoskeleton (Denver, CO). 
 
2.2.2 Cell Culture, transient transfection, and secretion assays 
MIN6 beta cells (a gift from Dr. John Hutton, University of Colorado Health Sciences 
Center, Denver, CO) were cultured in Dulbecco’s modified Eagle’s medium (25 mM glucose),  
supplemented with 15% fetal bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 292 
μg/ml L-glutamine, and 50 μM β-mercaptoethanol as described previously (201).  MIN6 cells 
were transfected with Transfectin (Bio-Rad) according to the manufacturer’s instructions and 
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cultured 48 h before use in experiments.  For experiments where cells were starved and 
stimulated, MIN6 cells were washed twice with and incubated for 2 h in freshly prepared 
modified Krebs-Ringer bicarbonate buffer (MKRBB: 5 mM KCl, 120 mM NaCl, 15 mM HEPES, 
pH 7.4, 24 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, and 1 mg/ml radioimmunoassay-grade 
BSA).  Cells were stimulated with 20 mM glucose as indicated and insulin secreted into the 
buffer was quantitated using a rat insulin radioimmunoassay kit (EMD Millipore, Billerica, MA).  
Cells were lysed in 1% Nonidet P-40 (NP-40) lysis buffer (25 mM HEPES, pH 7.4, 1% Nonidet 
P-40, 10% glycerol, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 137 mM NaCl, 1 
mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 1 μg/ml 
pepstatin, 5 μg/ml leupeptin)  and cleared of insoluble material by centrifugation for 10 min at 
4°C for subsequent use in co-immunoprecipitation experiments. 
 
2.2.3 Subcellular Fractionation 
As described previously (74), all fractionation steps were performed at 4°C.  Briefly, 
MIN6 cells at 70-80% confluence were harvested into 1 ml of homogenization buffer (20 mM 
Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 250 mM sucrose, 1 mM dithiothreitol, 100 μM 
phenylmethylsulfonyl fluoride, 4 μg/ml aprotinin, 2 μg/ml pepstatin, and 10 μg/ml leupeptin).  
Cells were homogenized by 10 strokes through a 27-gauge needle, and then centrifuged at 900 x 
g for 10 min.  Post-nuclear supernatants were centrifuged for 5500 x g for 15 min.  The resulting 
supernatant was centrifuged at 25,000 x g for 20 min to obtain the secretory granule fraction in 
the pellet.  This supernatant was centrifuged further at 100,000 x g for 1 h to acquire the cytosolic 
fraction.  The PM fraction was prepared by mixing the post-nuclear pellet with 1 volume of 
Buffer A (0.25 M sucrose, 1 mM MgCl2, and 10 mM Tris-HCl, pH 7.4) and 2 volumes of Buffer 
B (2 M sucrose, 1 mM MgCl2, 10 mM Tris-HCl, pH 7.4).  This mixture was overlaid with Buffer 
A and centrifuged at 113,000 x g for 1 h to obtain an interface containing the PM.  The interface 
was collected, diluted to 1.5 ml with homogenization buffer, and centrifuged at 6000 x g for 10 
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min.  The resulting pellet contained the PM fraction.  All collected pellets were resuspended in 
1% NP-40 lysis buffer. 
 
2.2.4 Co-immunoprecipitation and Immunoblotting 
For immunoprecipitation, 2-3 mg of cleared detergent lysate protein was combined with 
1 μg of antibody per mg protein and the reaction rotated for 2 h at 4°C.  Protein G Plus agarose 
beads (Santa Cruz) were added and reactions rotated at 4°C for an additional 2 h.  Beads were 
pelleted and washed three times with lysis buffer and resulting immunoprecipitates were resolved 
on 10-12% SDS-PAGE and transfer to PVDF membranes for immunoblotting.  Immunoreactive 
bands were visualized with ECL, ECL Prime (GE Healthcare, Piscataway, NJ), or Supersignal 
Femto (Pierce) reagents and imaged using a Chemi-Doc gel documentation system (Bio-Rad, 
Hercules, CA).  Phosphorylated and total ERK blots were visualized using goat anti-mouse 680 
and goat anti-rabbit 800 simultaneously and imaged on a Licor imaging system. 
 
2.2.5 Immunofluorescence, confocal microscopy and scoring F-actin remodeling 
MIN6 cells plated onto glass coverslips at 30% confluence were transiently transfected 
with 4 μg of plasmid DNA/35 mm well.  After 48 h incubation, cells were placed in MKRBB for 
2 h, followed by stimulation with 20 mM glucose for 5 min and then immediately fixed and 
permeabilized in fixation/permeabilization buffer (4% paraformaldehyde, 0.1% Triton X-100 at 
4°C) for 10 min in the dark.  Fixed and permeabilized cells were blocked in blocking buffer (1% 
BSA plus 5% donkey serum in PBS) for 1 h at room temperature, followed by incubation with 
0.17 μM Rhodamine-Phalloidin for 1 h, per manufacturer instructions.  MIN6 cells were then 
washed three times with phosphate-buffered saline (pH 7.4).  During the final wash, DAPI was 
added to stain nuclei.  All cells were washed again with PBS, and mounted (using Vectashield) 
for confocal fluorescence microscopy.  Fluorescent cells were imaged using single-channel 
scanning with a 60X objective (2X zoom) using an Olympus FV1000-MPE confocal microscope 
43 
 
(Olympus, Center Valley, PA).  To score F-actin remodeling, only cells on the outside of clusters 
were counted.  Cells with discontinuous cortical F-actin after 5 min of glucose stimulation were 
scored as exhibiting F-actin remodeling. 
 
2.2.6 Live-cell imaging 
MIN6 beta cells were plated on 35 mm glass-bottom MatTek culture dishes, grown to 30-
50% confluency and transfected with Lifeact-GFP.  48 h later cells were starved in MKRBB 
containing either DMSO or drugs as stated in figure legends.  For confocal live-cell imaging, 
cells were constantly perfused with MKRBB containing DMSO or IPA3 and imaged on an 
Olympus FV1000-MPE.  For Apotome live-cell imaging data was collected using a Zeiss Axio 
Observer with a Plan-Apochromat 63X objective equipped with a Hamamastu Orca-ER digital 
camera and an Apotome and analyzed using ImageJ software (NIH). 
 
2.2.7 Mouse islet isolation, perifusion, and islet immunoblot analysis 
All studies involving mice followed the Guidelines for the Use and Care of Laboratory 
Animals at Indiana University School of Medicine.  Wild type male C57BL/6J mice were 
sacrificed for pancreatic islet isolation as previously described (212).  Briefly, mouse islets were 
isolated from collagenase-perfused pancreata using a combination of puriﬁed collagenase 
(CIzyme MA, VitaCyte, Indianapolis, IN) and neutral protease (CIzyme BP Protease, VitaCyte).  
Islets were carefully handpicked and size-matched into batches of 50 islets per column for 
perifusion.  Perifusion studies were carried out as previously described (200).  Insulin secreted 
into the buffer and insulin content in the corresponding islet lysates was quantified by Rat Insulin 
RIA (Millipore).  To prepare stimulated islet samples for Western analysis, 100-200 islets were 
incubated for 1 h in KRBH buffer (10 mM HEPES pH 7.4, 134 mM NaCl, 5 mM NaHCO3, 4.8 
mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4 containing 0.5 mg/ml BSA) 
supplemented with 2.8 mM glucose.  Islets were then stimulated for 1 h in 16.7 mM glucose, 
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washed in cold PBS, and lysed and boiled in Laemmli sample buffer before SDS-PAGE and 
immunoblot analysis. 
 
2.2.8 Human Islet Culture 
Pancreatic human islets were obtained through the Integrated Islet Distribution Program, 
IIDP.  Criteria for human donor islet acceptance: receipt within 36 h of isolation, and of at least 
80% purity and 75% viability.  Upon receipt, human islets were first allowed to recover in CMRL 
medium for 2 h, and then were handpicked using a green gelatin filter to eliminate residual non-
islet material.  Human islets were then used immediately for glucose time course experiments by 
preincubation in KRBH for 2 h, followed by stimulation with glucose for the times indicated in 
the figures.  For IPA3 treatment, islets were cultured overnight in CMRL containing either 
DMSO or IPA3 (7.5 μM). 
 
2.2.9 Statistical Analysis 
All quantified data are expressed as mean ± S.E.  Data were evaluated using Student’s t 
test and considered significant if P < 0.05. 
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2.3 RESULTS 
 
2.3.1 PAK1is activated in human islets and is required for MEK activation 
 While it has been shown that PAK1 activation occurs in human islets and is dependent on 
upstream glucose-stimulated Cdc42 activation (45), whether the time course of activation in 
human islets mimics that observed in rodent cells was undetermined.  Toward this, human islets 
were preincubated at 2.8 mM glucose followed by incubation in 16.7 mM glucose for either 5, 10, 
or 20 minutes and lysed for immunoblot analysis.  We observed that PAK1 phosphorylation on 
Thr 423 was indeed increased by 5 min of glucose and was maintained at 10 and 20 min, similar 
to studies with mouse clonal MIN6 beta cells (Figure 2-1A).  ERK phosphorylation served as an 
indicator of islet responsiveness to glucose and was increased similarly in response to 5 min 
glucose stimulation (Figure 2-1A).  Furthermore, human islets that were pretreated overnight with 
the PAK1 inhibitor IPA3 exhibited reduced PAK1 phosphorylation on Thr 423 and reduced MEK 
phosphorylation on Ser 217/221 in response to glucose stimulation (Figure 2-1B), indicating that 
PAK1 signaling in human islets is required upstream for MEK activation.  We confirmed these 
results in MIN6 cells showing that MEK is activated in response to glucose by 5 min (Figure 2-
1C) and IPA3 can prevent MEK activation (Figure 2-1D).  These data demonstrate that PAK1 is 
necessary for MEK activation in both human islets and MIN6 cells, and that the MIN6 cell line is 
a suitable model to study PAK1 signaling. 
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Figure 2-1.  PAK1 is phosphorylated and is required for MEK activation in human islets.  A)  
Human islets were incubated in KRBH with 2.8 mM glucose for 2 h and then stimulated with 16.7 mM 
glucose for 0, 5, 10, and 20 min.  Islets were lysed for SDS-PAGE and immunoblotting for 
phosphorylated and total PAK1 and ERK1/2.  Data are representative of at least three different batches 
of human islets.  B)  Human islets were incubated overnight 15h in CMRL with containing either 
vehicle (DMSO) or 7.5 µM IPA3.  Islets were then incubated in KRBH with 2.8 mM glucose for 2 h, 
still in the presence of vehicle or IPA3, and then stimulated with 16.7 mM glucose for 5 min before 
harvest for SDS-PAGE and immunoblotting for either phosphorylated (pMEK1/2) and total MEK1/2 or 
phosphorylated (pPAK1) and total PAK1.  Blots shown for pPAK1/PAK and pMEK1/2/MEK1/2 are 
from different batches of islets.  C)  MIN6 cells were starved for 2 h in MKRBB before stimulation 
with 20 mM glucose for 0, 5, 10, 15, 20, and 30 min. Detergent whole cell lysates were collected and 
subjected to SDS-PAGE analysis and immunoblotting with antibodies to phosphorylated and total 
MEK1/2.  D)  MIN6 cells were treated as in (C) except the MKRBB contained either vehicle or 15 µM 
IPA3 for 1 h prior to the 5 min glucose before stimulation.  Data are representative of at least three 
independent experiments. 
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2.3.2 PAK1 activity is necessary for glucose-induced cortical F-actin remodeling 
To determine whether PAK1 activation is required for changes in cortical F-actin 
remodeling in response to glucose, we used the Lifeact-GFP biosensor (213).  Lifeact is a 17 
residue peptide from the actin binding protein Abp140 linked N-terminally to GFP as a fusion 
protein that has been shown to bind specifically to F-actin in live cells without adversely affecting 
F-actin dynamics.  Lifeact-GFP allows live cell imaging of F-actin dynamics, as previously 
demonstrated in beta cells (136, 211).  Glucose stimulation elicited visible changes in the cortical 
F-actin structure in control (DMSO) treated cells (Figure 2-2A), consistent with previously 
published work showing that glucose stimulation causes F-actin remodeling in beta cells (33, 137, 
143).  In contrast, cells that had been preincubated for 10 min with the PAK1 inhibitor IPA3 prior 
to glucose stimulation showed no glucose-induced changes to cortical F-actin structure (Figure 2-
2A).  Treatment with IPA3 had no adverse effect on the overall F/G-actin ratio under either basal 
or glucose-stimulated conditions (Figure 2-2B), indicating that the effect of IPA3-mediated PAK1 
inhibition on glucose-induced F-actin remodeling was not likely due to increased levels of 
cellular F-actin, but instead was suggestive of a block in glucose-induced actin remodeling. 
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Figure 2-2.  PAK1 activity is required for glucose-stimulated cortical F-actin remodeling in MIN6 
beta cells.  A)  MIN6 cells were transfected with Lifeact-GFP plasmid DNA and incubated to allow 
protein expression for 48 h.  Lifeact-GFP expressing cells were then preincubated for 2 h in MKRBB, 
and either vehicle (DMSO) or 30 µM IPA3 was added to the buffer 10 min before live-cell confocal 
imaging.  Images were collected every minute for 5 min.  Representative images of 11 cells from 3 
independent experiments assessing basal (0:00) and stimulated (5:00) Lifeact-GFP in MIN6 cells are 
shown.  Scale bar, 10 µm.  B)  MIN6 cells were preincubated in MKRBB for 2 h followed by a 10 min 
pretreatment with either DMSO or 30 µM IPA3.  Cells were harvested for F/G-Actin ratio analysis 
(F/G-actin ratio kit, Cytoskeleton, Inc).  Samples were subjected to SDS-PAGE and actin 
immunoblotting (IB).  S, supernatant (G-actin).  P, pellet (F-actin).  Data are representative of three 
independent experiments. 
50 
 
2.3.3 PAK1 activity is required for VAMP2-bound insulin granule accumulation at the 
PM in response to glucose 
While PAK1 is known to be required for second-phase insulin secretion, the exact 
mechanism(s) or downstream signaling pathway(s) which require PAK1 remained unclear.  
PAK1 may be required for granule recruitment to the PM, increasing the release competency of 
granules at the PM, or both.  We used subcellular fractionation of MIN6 beta cells to address 
whether PAK1 is required for VAMP2 accumulation at the PM during glucose stimulation.  
VAMP2 is the v-SNARE protein present on the insulin granule and known to be required for 
SNARE mediated insulin exocytosis (214), and therefore serves as a marker of insulin granule 
locale within the beta cell.  Since PAK1 is required for second phase insulin secretion, 20 min as 
opposed to 5 min of glucose stimulation was used to assay the impact of PAK1 inhibition on 
VAMP2 accumulation at the PM.  Compared to unstimulated cells, the ratio of VAMP2 between 
the PM and SG (secretory granule) fractions was significantly increased by ~40% after 20 min of 
glucose-stimulation, consistent with previous studies (Figure 2-3) (86).  However, cells treated 
with IPA3 followed by 20 min of glucose stimulation exhibited no increase in the VAMP2 
PM/SG ratio (Figure 2-3).  This data suggested that PAK1 activity may be required for insulin 
granule recruitment to and/or retention/capture at the PM. 
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Figure 2-3.  PAK1 is required for glucose-induced VAMP2 accumulation at the plasma 
membrane.  MIN6 cells were preincubated for 2 h in MKRBB and either vehicle (DMSO) or 30 µM 
IPA3 was added 10 min prior to stimulation with 20 mM glucose for 20 min.  Cells were harvested and 
subjected to subcellular fractionation to isolate plasma membrane (PM) and secretory granule (SG) 
fractions.  Samples from the PM and SG of stimulated and unstimulated cells were analyzed by SDS-
PAGE and immunoblotting and quantitation of VAMP2 by densitometry.  The amount of VAMP2 in 
the PM divided by the amount of VAMP2 in the SG yielded the VAMP2 PM/SG ratio which increased 
in response to glucose in control cells.  The bar graph represents the average ± S.E. for three 
independent experiments (*, P < 0.05, versus unstimulated DMSO). 
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2.3.4 ERK signaling contributes to the amplifying pathway of insulin secretion and 
cortical F-actin remodeling 
Having established PAK1 as an upstream signal required for MEK1/2 and ERK1/2 
activation, we next questioned whether PAK1-MEK-ERK signaling accounted for PAK1’s 
requirement in glucose-stimulated insulin secretion.  To test this, we monitored insulin secretion 
from MIN6 cells treated with the MEK inhibitor, PD03, to prevent ERK activation.  PD03 has a 
much lower IC50 than its predecessor MEK inhibitors PD98059 or U0126, and has very little 
activity against kinases other than MEK, allowing its use at lower concentrations that reduce the 
risk of off-target effects (181).  Low dosage PD03 treatment was first verified to block ERK 
activation by immunoblot analysis (Figure 2-4A), and was subsequently found to result in a 30% 
reduction in glucose-stimulated insulin secretion after 30 min of stimulation (Figure 2-4B).  Since 
a 30 min glucose stimulation will encompass insulin release during both phases, we next 
employed the diazoxide paradigm in an effort to examine the requirement for ERK in the 
amplifying phase of insulin secretion in MIN6 cells.  MIN6 cells were pretreated with either 
vehicle (DMSO) or PD03 for 2 h, followed by a 10 min pretreatment with diazoxide before 
stimulation with 30 mM KCl or 30 mM KCl plus 20 mM glucose.  Control cells showed a robust 
3-fold glucose-induced amplification response during the 30 min stimulation period (Figure 2-
4C).  By contrast, PD03-treatment caused a 30% reduction in glucose-amplified insulin secretion 
(Figure 2-4C).  In these cells, ERK activation was initiated by the triggering pathway conditions, 
but was heightened by the addition of glucose to activate the amplification pathway (Figure 2D).  
PD03 efficiently blocked ERK activation under all treatment conditions (Figure 2-4D).  To 
determine whether ERK’s role downstream of PAK1 in the amplifying pathway involved effects 
on cortical F-actin remodeling, MIN6 cells were pretreated with vehicle (DMSO) or PD03 for 2 h 
followed by a 5 min stimulation with glucose.  Control cells exhibited remodeling of F-actin after 
5 min of glucose stimulation, while the F-actin remodeling in PD03-treated cells was blunted 
(Figure 2-4E).  IPA3 treated cells served as a control and showed the expected blunting of 
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glucose-induced cortical F-actin remodeling (Figure 2-4E).  Given that PD03 efficiently blocked 
all ERK activity yet some insulin release attributable to the amplification was retained, it remains 
possible that PAK1-MEK-ERK may not be the exclusive signaling cascade to account for the 
amplification pathway of insulin secretion. 
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Figure 2-4.  ERK signaling contributes to the amplifying pathway and F-actin remodeling.  A)  
MIN6 cells were preincubated for 2 h in MKRBB containing either vehicle (DMSO) or 1 µM PD03 and 
then stimulated with 20 mM glucose for 30 min.  Lysates were subjected to SDS-PAGE and 
immunoblotting for phosphorylated and total ERK1/2.  B)  Insulin secreted into the MKRBB from 
MIN6 cells in (A) was measured.  Bars represents the mean ± S.E. of at least three independent 
experiments from (C) (*, P < 0.05, versus DMSO).  C)  MIN6 cells treated as in (A) were exposed to 
250 mM diazoxide (Dz) for 10 min before stimulation with 35 mM KCl or 35 mM KCl plus 20 mM 
glucose for 30 min.  Supernatants were collected for insulin radioimmunoassay.  Bar graph represents 
the mean ± S.E. of at least three independent experiments (*, P < 0.05, versus DMSO).  D)  Lysates 
from (C) were subjected to SDS-PAGE and immunoblot (IB) analysis for phosphorylated and total 
ERK1/2.  E)  MIN6 cells plated on glass cover slides were pre-incubated in MKRBB for 2 h and left 
unstimulated (top panels) or stimulated with 20 mM glucose for 5 min (bottom panels).  Cells were 
fixed, permeabilized and cortical F-actin detected by Rhodamine-Phalloidin staining.  Cells were 
imaged at the midplane by single channel scanning confocal microscopy to determine F-actin 
remodeling.  Arrows indicate cortical regions of MIN6 cells.  Scale bar, 10 µm.  Bar graph represents 
the mean % cells exhibiting F-actin remodeling ± S.E. of three independent experiments where each 
experiment contained 6 to 12 fields of cells.  (*, P < 0.05, stimulated DMSO versus unstimulated 
DMSO, ** P < 0.05, versus stimulated DMSO). 
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2.3.5 ERK activation is important for insulin secretion in mouse islets 
A central tenet regarding the importance of second phase insulin secretion purports that 
granules mobilized towards the PM during the end of this phase serve as the pool of granules 
released in the subsequent round of GSIS (23, 32).  To determine the requirement for ERK 
activity in this paradigm we perifused islets pre-treated with PD03 for 30 min through a full 
round of first and second phase which was normal (data not shown), rested the islets for 20 min at 
2.8 mM glucose still in the presence of DMSO or PD03, and then subjected them to a subsequent 
round of stimulation using 30 mM KCl (Figure 2-5A).  KCl is known to elicit rapid exocytosis of 
granules pre-docked at the PM (2).  Compared with control vehicle treated islets, the PD03-
treated islets secreted ~50% less insulin in response to KCl stimulation (Figure 2-5B, C).  The 
ability of PD03 to prevent ERK activation was confirmed in islets subjected to this treatment 
paradigm (Figure 2-5C).  Islet insulin content was unchanged by PD03 treatment (Figure 2-5D).  
These data may implicate ERK in the refilling of the readily releasable pool after a glucose 
challenge, and are consistent with the requirement for PAK1 signaling to ERK to elicit second-
phase insulin secretion. 
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Figure 2-5.  ERK signaling is required for insulin secretion after a repeated stimulation.  A)  50 
size-matched mouse islets were perifused in KRBH in the constant presence of either vehicle (DMSO) 
or 1 µM PD03.  Islets were first perifused under 2.8 mM glucose for 30 min, then 16.7 mM glucose for 
35 min, followed by a 20 min rest period at 2.8 mM glucose.  The islets were then stimulated with 35 
mM KCl and 2.8 mM glucose for 10 min.  Insulin content of the perifusate and the islets was 
determined by insulin radioimmunoassay.  Trace is the average of three independent experiments.  B)  
Bar graph represents the mean area under the curve (AUC) normalized to DMSO treatment ± S.E. of 
three independent experiments from (A).  AUC was calculated from the 10 min duration of KCl 
stimulation (66 to 75 min) (*, P < 0.05, versus DMSO).  C)  Mouse islets were preincubated in KRBH 
with 2.8 mM glucose in the presence of either DMSO or 1 µM PD03 for 1 h followed by stimulation 
with 16.7 mM glucose for 10 min.  Islets were lysed and subjected to SDS-PAGE and immunoblotting 
for phosphorylated and total ERK1/2.  D)  Insulin content was measured in islets from perifusion 
experiments in (A) with an insulin RIA kit.  Bar graph represents the mean ± S.E. of three independent 
experiments. 
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2.3.6 PAK1 signaling is coupled to F-actin-Syntaxin 4 interactions 
 Since PAK1 impacts glucose-induced F-actin remodeling and is required for second 
phase insulin secretion, we investigated how PAK1 might affect the t-SNARE known to directly 
interact with F-actin, Syntaxin 4.  Syntaxin 4 is an important SNARE protein since it is required 
for both phases of insulin secretion and is the only Syntaxin operative in second phase (39).  
Syntaxin 4-F-actin complexes exist under unstimulated conditions and dissociate after 5 min of 
glucose stimulation (64).  At this same time, PAK1 is activated and F-actin remodeling is 
underway (33, 43).  To investigate whether PAK1 signaling was coupled to Syntaxin 4-F-actin 
interactions, PAK1 activation was inhibited with IPA-3 in MIN6 cells and the cell lysates were 
used in Syntaxin 4 coimmunoprecipitation experiments.  Under control conditions, F-actin was 
found to associate with Syntaxin 4 (Syntaxin 4 binds only to F- and not to G-actin (64)), and 
dissociated after 5 min of glucose stimulation (Figure 2-6), consistent with previous findings (64) 
and with the timing and occurrence of glucose-induced actin remodeling in beta cells. However, 
IPA-3 treatment resulted in F-actin dissociation from Syntaxin 4 under basal conditions, and the 
Syntaxin 4-F-actin complexes were further unresponsive to glucose stimulation (Figure 2-6).  
Unlike F-actin, SNAP-25 binding to Syntaxin 4 was similar under all conditions, suggesting a 
specific effect of IPA3-mediated inhibition of PAK1 on Syntaxin 4-F-actin complexes.  These 
data suggest that glucose-induced PAK1 signaling is important for the normal cycling of Syntaxin 
4-F-actin association/dissociation. 
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Figure 2-6.  PAK1 signaling is linked to Syntaxin 4-F-actin complex regulation.  MIN6 cells were 
preincubated in MKRBB for 2 h and then treated with either vehicle (DMSO) or 30 µM IPA3 for 10 
min before stimulation with 20 mM glucose for 5 min.  Detergent lysates were collected and used in 
anti-Syntaxin 4 (Syn4) immunoprecipitation (IP) experiments.  Association of SNAP-25 and actin was 
determined by immunoblotting (IB).  Band intensities were quantitated by densitometry and expressed 
as the ratio of actin to Syn4 (normalized, basal ratio = 1 for each experiment).  Bars represent the mean 
± S.E. of the three independent experiments (*, P < 0.05, versus unstimulated DMSO). 
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2.4 DISCUSSION 
 
 While PAK1 is required in the second phase of glucose-stimulated insulin secretion, how 
PAK1 is acting to carry out this task was unclear.  Here we establish an importance for PAK1 
signaling to F-actin cytoskeletal remodeling to facilitate glucose-stimulated insulin secretion.  By 
use of kinase-selective inhibitors we mapped for the first time the signaling itinerary of PAK1 in 
the islet beta cell: PAK1-MEK-ERK.  Moreover, each step was shown to be important for GSIS, 
specifically for the amplification pathway, suggesting this to be a linear cascade of events.  
PAK1-MEK-ERK signaling was also demonstrated to be critical for normal glucose-induced F-
actin remodeling.  In addition to its role in overall F-actin remodeling, PAK1 activation was 
implicated in the normal glucose-induced cycling of Syntaxin 4-F-actin association/dissociation.  
Since PAK1 activation was also required for VAMP2 accumulation at the PM, taken together 
these data are suggestive of a proximal role for PAK1 in a signaling pathway which leads 
downstream to F-actin-mediated trafficking and SNARE docking of insulin granules at the PM to 
elicit sustained exocytosis as shown in the model in Figure 2-7. 
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Figure 2-7.  Model of Cdc42-PAK1 signaling in the beta cell.  Glucose enters the beta cell, activating 
Cdc42 and PAK1.  PAK1 signaling then regulates Syntaxin 4-F-actin complexes,  VAMP2 
accumulation at the plasma membrane, and MEK-ERK signaling to regulate amplification of insulin 
secretion and F-actin remodeling.  Syn4, Syntaxin 4. 
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Glucose-stimulated activation of ERK lies downstream of PAK and MEK in the beta cell, 
but MEK activation is canonically regulated by the Raf kinases (173).  Additionally, both C-Raf 
(also called Raf-1) and B-Raf have been investigated in beta cells for roles in GSIS (95, 215).  B-
Raf, but not C-Raf was activated by glucose in MIN6 cells (215), while in INS-1 832/13 cells use 
of the C-Raf inhibitor GW-5074 prevented ERK and Rac activation and inhibited GSIS (95).  It is 
suggested that B-Raf activation may have a role early in glucose-stimulated ERK activation (from 
5 to 15 min post-stimulation) while C-Raf may have a role at later time points (1 h post-
stimulation) (215).  PAK1 has been shown to phosphorylate both MEK and C-Raf (87, 175, 176) 
and constitutively active PAK1 decreased auto-inhibition of B-Raf (216).  Our data combined 
with these observations suggest that in addition to direct activation of MEK, PAK1 may act 
through B-Raf/C-Raf to activate MEK and ERK in response to glucose.  Since ERK activation 
was important for glucose-stimulated F-actin remodeling, future investigation will be required to 
elucidate the downstream effectors of ERK that mediate this effect. 
 Our results contribute to a growing body of data supportive of a role for ERK activation 
in the amplifying pathway.  The existing data are a combination of findings using siRNA-
mediated knockdown of Raf/ERK and MEK inhibitor treatments in beta cells (95, 180, 217).  
Additionally, our finding that ERK is further activated in response to the amplifying signal is 
consistent with its potentiated activation by factors like GLP-1 (218, 219).  Furthermore, 
inhibition of ERK activation was shown to prevent GLP-1-potentiated secretion in INS-1 cells, 
implicating it further in the amplifying pathway (217).  Combined, my data contrast with earlier 
findings that ERK was involved only in a mitogenic role in beta cells (220).  It is possible that use 
of the older MEK inhibitor, PD98059, may have contributed to the controversy.  There were no 
defects in insulin content in islets treated with PD03 for short periods (2 h), suggesting that 
expression of insulin at the protein level was not impacted by the blocked ERK activation.  It is 
unclear in cases where ERK signaling has been blocked for short periods whether transcriptional 
effects might account for reduced secretory capacity.  Future investigations will require large-
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scale gene expression analyses of basal and glucose-stimulated beta cells under time courses with 
MEK inhibitors like PD03 to determine whether changes in gene expression may underlie any of 
ERK’s roles in GSIS.  Our results in PD03-treated mouse islets do support published work 
showing ERK has a role in secretion from perifused islets (180), although we found the effect of 
ERK activation to consistently be required for a full response to a subsequent stimulation with 
KCl as opposed to effects in first or second phase GSIS.  Prior work has shown that inhibition of 
MEK with PD98059 in rat islets did not impair Ca
2+
 uptake (180) and we saw no defect in the 
first phase of glucose stimulated insulin secretion, suggesting that the PD03-induced defect in 
secretion after the rest period was not due defective Ca
2+
 influx.  Differences between mouse and 
rat islets or potential off-target effects of PD98059 could underlie why perifusion of rat islets with 
PD98059 caused an overall reduction in basal and biphasic insulin secretion (180), while in our 
study perifusion of mouse islets with PD03 only blunted the response to a subsequent stimulation.  
Because PD03 likely blocked ERK activation in other cell types of the islet, potentially 
confounding our results by indirectly affecting the islet beta cells, we chose to investigate the 
effects of PD03 treatment on insulin secretion using MIN6 cells which contains only beta cells.  
Our studies in MIN6 cells also showed that ERK is necessary for cortical F-actin remodeling.  
Although prior studies suggested that inhibition of ERK signaling had no impact on glucose-
induced F-actin remodeling, those prior studies focused on stress fibers, not cortical F-actin (96).  
Since ERK has a partial role in amplification, this suggests that signaling pathways in addition to 
ERK emanating from PAK1 may fulfill the remainder of the role of PAK1 in amplification.  
Studies assessing other PAK1 targets in beta cells and their potential roles in F-actin remodeling 
and insulin secretion are currently ongoing in our lab. 
Since PAK1 is required for second phase insulin secretion, the question arises as to 
whether PAK1 signaling cross-talks with other pathways such as the GLP-1 stimulated signaling 
pathway to impact second phase GSIS.  If PAK1 is activated downstream of cAMP, this could 
suggest integration with GLP-1 signaling to enhance second phase insulin secretion.  GLP-1 acts 
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on the beta cell via the GLP-1 receptor which activates adenylyl cyclase to produce cAMP which 
activates both PKA and Epac2 (221).  GLP-1 is one of the only known therapeutics that can 
increase both phases of insulin secretion in diabetic patients (222).  Since signaling through both 
cAMP-PKA and PAK1 act in second phase insulin secretion it is tempting to speculate that PAK1 
may have a role in GLP-1 action.  PKA activation is also important for ERK activation.  Multiple 
stimuli (GLP-1, forskolin) that increase cAMP levels in beta cells also potentiate ERK activation 
(219, 223).  Consistently, PKA inhibitors (H-89) prevent glucose stimulated ERK activation (180, 
219).  Recent work suggests that cAMP might signal to PAK1 activation in beta cells through the 
kinase called Synapses of Amphids Defective (SAD-A) (224), although there are conflicting roles 
for SAD-A in insulin secretion which require further investigation (225).  SAD-A can directly 
activate PAK1 (224), although it is unknown whether this depends on Cdc42.  Therefore, future 
studies will be required to fully determine the linkage between Cdc42-PAK1, cAMP-PKA, and 
ERK signaling in glucose-stimulated biphasic insulin secretion and F-actin remodeling. 
While PAK1 is required for downstream activation of Rac1 and ERK in beta cells, the 
identities of direct substrates for PAK1 in the beta cell are lacking.  PAK1 has many known 
targets in other cell types that are likely beta cell targets as well, including MEK, Filamin A, 
MLC2, and RhoGDI.  As a start, I have found that blocking PAK1 activation reduced MEK 
activation.  This opens the possibility that MEK may be a target of PAK1 in response to glucose, 
although PAK1 could be signaling through Raf to MEK.  Secondly, I have observed Filamin A 
and MLC2 phosphorylation in response to glucose; although it is currently unknown whether 
these events depend on PAK1 (Kalwat and Thurmond, unpublished data).  Third, RhoGDI 
phosphorylation by PAK1 is known to cause its dissociation from Rac1 (84), and 
phosphomimetic mutants of RhoGDI show decreased Rac1 association in beta cells (44).  These 
targets, and potentially others, may account for PAK1’s effects on insulin secretion that cannot be 
attributed to ERK alone. 
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F-actin cytoskeletal architecture seems to have a role in regulating amplitude of glucose-
stimulated ERK activation (96).  Depolymerization of F-actin with latrunculin led to potentiated 
glucose-stimulated ERK activation (96).  This active ERK was shown to be localized to the tips 
of actin filaments (96), placing it in the proper compartment to 1) act on proteins that could be 
involved in insulin secretion and 2) to be regulated downstream of PAK1.  However, other well-
characterized candidate PAK1 target pathways that might have a role in glucose-induced F-actin 
remodeling such as LIM kinase-cofilin, PAK1-Filamin A, and MLCK-myosin regulatory light 
chain 2 (MLC2) must also be considered.  With regards to LIMK-cofilin, we recently 
demonstrated that PAK1 KO islets were unresponsive to changes of phospho-cofilin/cofilin under 
any conditions (45).  Moreover, no changes in phospho-cofilin/cofilin content were observed in 
MIN6 beta cells, suggesting against LIMK-cofilin as a primary route for PAK1 signaling to the 
actin cytoskeleton (45).  Filamin A is a known target of PAK1, specifically Filamin A Ser 2152, 
and phosphorylation at this site is necessary for Filamin’s role in F-actin dynamics (90, 226).  Our 
preliminary observations suggest Filamin A Ser 2152 is phosphorylated in beta cells in response 
to glucose (data not shown), but this will require future investigation for importance as a PAK1 
target in the beta cell.  PAK1 also targets MLCK and MLC2 phosphorylation by MLCK is known 
to promote actin remodeling processes in other cell systems (166).  Phosphorylated MLC has 
been reported in MIN6 beta cells (227) with MLC2 phosphorylation of serine19 induced in 
response to glucose stimulation (169, 228).  Since ERK can signal to MLCK in other cell types, it 
remains possible that PAK1 signals through MLCK/MLC2 directly and/or indirectly via ERK.  
Experiments are underway to determine the relative importance of PAK1 signaling to MLCK- 
MLC2 for glucose-induced actin remodeling. 
Our results showed that inhibition of PAK1 with IPA3 led to a decrease in Syntaxin 4-F-
actin binding under unstimulated conditions, as well as loss of glucose-regulation of this 
complex.  Disruption of Syntaxin 4-F-actin complexes can have positive or negative effects on 
insulin secretion or insulin granule recruitment to the PM depending on the circumstances.  For 
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example, under normal conditions glucose stimulation dissociates Syntaxin 4-F-actin complexes 
and is correlated with normal GSIS (33, 64, 143).  Addition of a small competitive peptide known 
to disrupt Syntaxin 4-F-actin complexes results in potentiated GSIS and VAMP2-bound insulin 
granule accumulation at the PM  (64).  Similarly, latrunculin treatment depolymerizes F-actin and 
thereby releases Syntaxin 4 from F-actin association, which also correlates with potentiated GSIS 
(33, 64).  Conversely, disruption of Syntaxin 4-F-actin as well as Syntaxin 4-Gelsolin complexes 
using a different competitive peptide leads to increased basal insulin release from mouse islets 
(143).  Syntaxin 4 leads to increased basal secretion as well (210).  In each of these three cases, 
increased basal or glucose-stimulated insulin secretion is associated with increased Syntaxin 4 
accessibility to docking VAMP2-bound insulin granules.  As such, it will be imperative in future 
studies to detail downstream PAK1 signaling to ERK and other substrates to understand how 
PAK1 regulates F-actin remodeling and Syntaxin 4-F-actin complex dynamics as they pertain to 
GSIS. 
 In summary, I determined that PAK1 is required for glucose-stimulated F-actin 
remodeling and VAMP2 accumulation in plasma membrane fractions.  Additionally, I showed 
that PAK1 signals to the ERK pathway through MEK in beta cells and that MEK-ERK signaling 
is necessary for normal glucose-induced insulin secretion and F-actin remodeling.  Finally, I 
linked PAK1 to Syntaxin 4-F-actin complex regulation, implicating the Cdc42-PAK1 pathway in 
the final steps of exocytosis.  Since PAK1 has been implicated in both glucose-stimulated insulin 
secretion and insulin-stimulated glucose uptake, it is clear that specifically enhancing PAK1 
signaling in certain tissues is a potential strategy for therapeutic intervention for type 2 diabetes.  
Since PAK1 protein levels are significantly decreased in type 2 diabetic human islets, treatments 
that act through the Cdc42-PAK1 pathway may not be effective unless PAK1 levels are restored.  
In addition, these results have implications in other secretory cell systems relevant to type 2 
diabetes where PAK1 may play a vital role, such as GLP-1 secretion from enteroendocrine L cells 
of the gut (229). 
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CHAPTER 3.  GELSOLIN ASSOCIATES WITH THE N-TERMINUS OF SYNTAXIN 4 
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3.1 INTRODUCTION 
 
 In response to a sharp increase in glucose concentration such as that induced by intake of 
a meal, pancreatic islet beta cells secrete insulin, doing so in a highly regulated and biphasic 
manner (30).  The first phase is rapid and robust, occurring within 10 minutes of stimulation, and 
thought to be accounted for by a readily-releasable pool of granules already present at the PM.  
The second phase follows at a sustained, lower rate of secretion that can last for hours (32), and is 
elicited only in response to fuel-type secretagogues such as glucose.  In order for insulin to be 
secreted, insulin granules must fuse with the PM in a stimulus-dependent and highly regulated 
manner; this process is carried out by soluble N-ethylmaleimide sensitive factor attachment 
receptor (SNARE) proteins (214, 230-232).  Two known functional target membrane-SNARE (t-
SNARE) isoforms from the Syntaxin protein family, Syntaxin 1A and Syntaxin 4, facilitate 
selective insulin granule fusion in beta cells via functioning as docking sites at the PM; Syntaxin 
1A is required only for first phase secretion, while Syntaxin 4 is important for both first and 
second phases (39, 42).  Both syntaxin isoforms pair with a second t-SNARE, SNAP-25, under 
both unstimulated/basal and stimulated conditions (33, 64).  Insulin granules are equipped with 
the vesicle-SNARE (v-SNARE) protein VAMP2/synaptobrevin (194), and upon arrival at the 
PM, form heterotrimeric SNARE core complexes by docking with t-SNAREs to facilitate 
membrane fusion (reviewed in (192, 195)).  Importantly, insulin release must be clamped under 
basal conditions, to provide the steep gradient necessary for a regulated stimulus response to 
appropriate secretagogues.  Defects in clamping unsolicited insulin exocytosis are associated with 
elevated basal insulin levels and are disruptive to maintenance of glucose homeostasis in vivo 
(233). 
 To sustain insulin release, mature insulin granules in intracellular storage pools must be 
mobilized toward the PM.  This process appears to coincide with glucose-induced remodeling of 
the actin cytoskeleton (33, 65, 128).  F-actin functions as a barrier to restrain insulin granule 
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accumulation at the PM (1, 109), such that its depolymerization results in more morphologically 
docked granules and may confer release competence (34, 64).  Evidence of positive effects of the 
cytoskeleton in stimulus-induced insulin secretion exists as well (129-132).  In fact, insulin 
granules are known to interact with F-actin filaments, and require microtubule tracks upon which 
to traffic to the F-actin network toward the PM (133, 234, 235).  Beyond impact upon trafficking, 
disruption of F-actin remodeling with agents that induce either F-actin disassembly or 
polymerization reveals that both actions jointly impact stimulated exocytosis outcomes (236).  F-
actin reorganization is important for stimulated exocytosis in many cell types other than beta 
cells, including neuroendocrine cells, adrenal chromaffin cells, platelets, and endothelial cells 
(119, 237, 238).  In addition to controlling stimulated exocytosis, the actin cytoskeleton affects 
control of basal exocytosis through Focal Adhesion Kinase, EphA-Ephrin-A signaling, and cell 
contact (132, 136, 239).  However, molecular mechanisms to describe how the cytoskeleton 
might participate in clamping of exocytotic machinery to ensure low levels of insulin secretion in 
the absence of stimuli remain unresolved. 
 Multiple SNARE proteins are linked with the F-actin cytoskeleton (64, 119, 205), 
although only Syntaxin 4 can directly interact with F-actin in vitro.  Granule docking at Syntaxin 
4 sites may be an important limiting factor in insulin exocytosis, given that increasing the number 
of Syntaxin 4 docking sites in vivo augments biphasic insulin secretion, while maintaining normal 
low basal levels (39).  Syntaxin 4 binds to F-actin via a spectrin-like region within the first two 
coiled-coil domains of the N-terminus of Syntaxin 4 (64).  Use of this region as a competitive 
peptide inhibitor reduces endogenous F-actin-Syntaxin 4 complex formation, concomitant with 
enhanced glucose-stimulated insulin secretion from MIN6 beta cells.  While these data argue that 
F-actin anchors at Syntaxin 4 sites at the plasma membrane, the potential roles of multiple actin 
binding proteins which are implicated in, or shown to be necessary for, proper glucose-stimulated 
insulin secretion have yet to be tested for integration into this particular mechanism (35, 43, 96, 
129).  One particular protein of interest is Gelsolin, an F-actin-severing/capping protein that plays 
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a positive role in insulin secretion, and has been proposed to be important for glucose-induced F-
actin remodeling which occurs in beta cells through an undefined mechanism (96, 153). 
 In this study, we provide the first evidence for formation of a novel and direct interaction 
between Syntaxin 4 and Gelsolin, mediated via the N-terminal Ha domain of Syntaxin 4.  In beta 
cells, this complex is dissociated in response to acute glucose- or KCl-stimulation.  Introduction 
of an Ha-domain peptide (amino acid residues 39-70) into MIN6 beta cells mimicked the action 
of these secretagogues by inducing dissociation of endogenous Syntaxin 4-Gelsolin complexes.  
Functionally, these binding alterations were accompanied by elevated basal insulin release in 
mouse islet and MIN6 beta cells, coordinate with inappropriate activation of Syntaxin 4.  The 
peptide-induced dissociation of Syntaxin 4-Gelsolin complexes in MIN6 beta cells also 
attenuated acute glucose- and KCl-stimulated insulin exocytosis, coinciding with attenuation of 
the KATP-channel dependent triggering pathway in the diazoxide paradigm.  These data support a 
new model for a clamping mechanism underlying regulated SNARE protein-mediated exocytosis.  
Given that 1) Gelsolin and Syntaxin 4 are ubiquitously expressed proteins; 2) F-actin remodeling 
occurs in non-beta cell types; and 3) the effects upon insulin exocytosis are not secretagogue-
specific, we propose that this mechanism may be applicable to regulated exocytosis events on a 
broader cell biological basis. 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Materials 
Two rabbit polyclonal anti-Syntaxin 4 antibodies were obtained for use in 
coimmunoprecipitation (Chemicon, Temecula, CA) and for immunoblotting (in-house, described 
in (210).  Rabbit anti-GFP and anti-GAPDH antibodies were obtained from Abcam (Cambridge, 
MA).  Monoclonal mouse anti-GFP, mouse anti-Cdc42, and mouse anti-Gelsolin antibodies were 
purchased from Clontech/BD Biosciences (Mountain View, CA).  Rabbit anti-actin antibody, 
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Flag-M2 antibody, DAPI, nifedipine and diazoxide were purchased from Sigma (St. Louis, MO).  
Latrunculin B was obtained from Calbiochem.  Rabbit anti-GST was obtained from Affinity 
Bioreagents (Golden, CO).  Rabbit anti-phospho-αPak1 (Thr423) was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Rabbit IgG and rabbit anti-αPak1 were purchased from Cell 
Signaling (Danvers, MA).  Fura-2/AM and Rhodamine-Phalloidin were purchased from 
Invitrogen (Carlsbad, CA).  The MIN6 cells were a gift from Dr. John Hutton (University of 
Colorado Health Sciences Center).  Goat anti-mouse horseradish peroxidase secondary antibody 
was obtained from Thermo Fisher Scientific (Rockford, IL).  Goat anti-rabbit horseradish 
peroxidase secondary antibody and TransFectin lipid reagent were acquired from Bio-Rad 
(Hercules, CA).  ECL reagent and Supersignal Femto were purchased from GE Healthcare 
(Piscataway, NJ) and Pierce, respectively.  The rat insulin radioimmunoassay kits were obtained 
from Millipore (Billerica, MA). 
 
3.2.2 Plasmids 
The pGEX4T-1 plasmids containing rat Syntaxin 4 residues 1-273, -1-194, -1-112, and 1-
70 and pEGFP-C2 plasmids containing Syntaxin 4 residues 1-273, 1-194, and 39-112 were 
previously described (64).  A PCR-generated DNA insert comprising the 39-70 residue region of 
Syntaxin 4 was subcloned into the 5' EcoRI and 3' XhoI sites of the pEGFP-C2 vector (Clontech) 
to generate pEGFP-Syntaxin 4-39-70; GFP-Scr (scrambled helical peptide) was inserted similarly 
using annealed primer set sequences: 5’sense strand: 
attcatgaagttcttcgacaccaagaaggtggagctggagctgacccagatcgtgcagatggagcagatcgagcagctgagcaggaagca
gaccagggccgtgtagg-3’.  GFP-Scr helicity was predicted to be 87.5%, that closest in helicity to 
GFP-39-70 that also failed to match with any known mouse peptides in BLAST.  The pGFP-39-
70-Ad adenoviral expression plasmid was generated by subcloning the GFP-39-70 DNA into the 
5’ BamHI and 3’ NotI sites of the pAdCMVK vector (Viraquest, Inc., North Liberty, IA); after 
which adenoviral production was carried out by Viraquest, Inc.  The pIRES-GFP-Gelsolin-Flag 
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plasmid was generated by subcloning DNA comprising only the cytoplasmic isoform (missing 
residues 1-50 of full-length protein) from the full length mouse cDNA purchased from 
Openbiosystems (Huntsville, AL) into the 5’ NheI and 3’ XhoI sites of the pIRES-GFP-3XFlag 
vector; the modified vector was a gift of Dr. Raj Khanna (Indiana University School of Medicine, 
IN).  All constructs were verified by DNA sequencing. 
 
3.2.3 Recombinant Proteins and Interaction Assays 
All GST fusion proteins were expressed in Escherichia coli and purified by glutathione-
sepharose affinity chromatography as described previously (64).  GST-Syntaxin 4 truncation GST 
proteins (20 μg) immobilized on sepharose beads were incubated with 20 μg of recombinant his-
tagged human Gelsolin protein (Cytoskeleton, Inc) in a 0.25 % NP-40 containing lysis buffer (25 
mM HEPES, pH 7.4, 0.25% Nonidet P-40, 10% glycerol, 50 mM sodium fluoride, 10 mM 
sodium pyrophosphate, 137 mM NaCl, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl 
fluoride, 10 μg/ml aprotinin, 1 μg/ml pepstatin, 5 μg/ml leupeptin) for 2 h at 4°C.  Following 
three washes with PBS, bound proteins were eluted from the sepharose beads and proteins 
resolved on 10% SDS-PAGE followed by transfer to PVDF membrane for immunoblotting. 
 
3.2.4 Cell Culture, Transient Transfection, Adenoviral Transduction, 
and Secretion Assays 
MIN6 beta cells were cultured in DMEM (25 mM glucose) supplemented with 15% fetal 
bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 292 μg/ml L-glutamine, and 50 
μM β-mercaptoethanol as described previously (201).  MIN6 beta cells at ~60-70% confluence 
were transfected using cesium chloride-purified plasmid DNA with TransFectin (Bio-Rad) to 
obtain ~30-50% transfection efficiency.  Electroporation of MIN6 cells was carried out as 
previously described (240). After 48 h of incubation, cells were washed twice with and incubated 
for 2 h in freshly prepared modified Krebs-Ringer bicarbonate buffer (MKRBB: 5 mM KCl, 120 
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mM NaCl, 15 mM HEPES, pH 7.4, 24 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, and 1 mg/ml 
radioimmunoassay-grade BSA).  Cells were stimulated with 20 mM glucose for the times 
indicated in the figures, after which the buffer was collected and centrifuged for 10 min at 4°C to 
pellet cell debris, and insulin secreted into the buffer was quantitated using a rat insulin 
radioimmunoassay kit (Millipore).  Cells were harvested in 1% NP-40 lysis buffer (same as 
0.25% NP-40 with exception of 1% Nonidet-P40), lysed for 10 min at 4°C, and were cleared of 
insoluble material by centrifugation for 10 min at 4°C for subsequent use in co-
immunoprecipitation experiments.  For adenoviral overexpression, MIN6 cells at 50-60% 
confluence were transduced at an MOI of 100 for 2 h, washed twice with PBS, and incubated in 
complete media for 48 h.  Cells were subsequently preincubated in MKRBB, subjected to 
stimulation, and harvested for generation of detergent cell lysates as described above. 
 
3.2.5 Co-immunoprecipitation and Immunoblotting 
For each immunoprecipitation, 2-3 mg of cleared detergent lysate protein was combined 
with 1 μg of antibody per mg protein and the reaction rotated for 2 h at 4°C.  Protein G Plus 
agarose beads (Santa Cruz) were added and reactions rotated at 4°C for an additional 2 h.  Beads 
were pelleted and washed three times with lysis buffer and resulting immunoprecipitates were 
resolved on 10-12% SDS-PAGE and transfer to PVDF membranes for immunoblotting.  
Immunoreactive bands were visualized with ECL or Supersignal Femto reagents and imaged 
using a Chemi-Doc gel documentation system (Bio-Rad). 
 
3.2.6 Calcium Imaging 
MIN6 cells transduced as described above were preincubated in MKRBB for 2 h, with 
Fura-2 AM (5 μM) added to the cells for an additional 25 min as reported previously (211, 241).  
Cells were washed with MKRBB to remove excess Fura-2 AM and placed in fresh MKRBB 
containing low (2 mM) glucose and KCl (5 mM).  Cells were imaged under constant perfusion (1 
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ml/min) for 300 seconds, followed by stimulation with 35 mM KCl to elicit calcium influx for 
300 seconds.  Fura-2 AM was excited at 340 and 380 nm, and emission captured at 510 nm on a 
Zeiss Axio Observer Apochromat 100X/1.46 objective equipped with a Hamamastu Orca-ER 
digital camera and analyzed using AxioVision 4.7 software (Carl Zeiss, Germany).  Fura-2 has 
been shown to exhibit similar fluorescence from cells untransfected or transfected with GFP 
(242). 
 
3.2.7 Immunofluorescence and Confocal Microscopy 
MIN6 cells plated onto glass coverslips at 30% confluence were transiently transfected 
with 4 μg of plasmid DNA/35 mm well.  After 48 h incubation, cells were placed in MKRBB for 
2 h, followed by stimulation with 20 mM glucose for 5 min and then immediately fixed and 
permeabilized in 4% paraformaldehyde and 0.1% Triton X-100 for 10 min at 4°C.  Fixed and 
permeabilized cells were blocked in 1% BSA plus 5% donkey serum for 1 h at room temperature, 
followed by incubation with 0.17 μM Rhodamine-Phalloidin for 1 h, per manufacturer 
instructions.  MIN6 cells were then washed three times with phosphate-buffered saline (pH 7.4).  
During the final wash, DAPI was added to stain nuclei.  All cells were washed again with PBS, 
and mounted (using Vectashield) for confocal fluorescence microscopy.  EGFP and Rhodamine 
fluorescing cells were imaged using single-channel scanning with a ×60 objective under a 2X 
zoom using an Olympus FV1000-MPE confocal microscope (Olympus, Center Valley, PA). 
 
3.2.8 Mouse Islet Isolation, Transduction, Perifusion, and Static Culture 
All studies involving mice followed the Guidelines for the Use and Care of Laboratory 
Animals at Indiana University School of Medicine.  Wild type male C57BL/6J mice were 
sacrificed for pancreatic islet isolation as previously described (39).  All viruses were obtained 
from Viraquest, Inc.  Freshly isolated islets were immediately transduced with 10
7
 pfu/islet with 
either GFP-Ad or GFP-39-70-Ad CsCl-purified particles for 1 h at 37°C in RPMI-1640 medium, 
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washed twice with PBS and incubated 48 h at 37°C/5% CO2.  GFP fluorescence was visualized 
in greater than 60-70% of islet cells with even penetration to the islet core.  GFP positive islets 
were handpicked into batches of 10/tube for static secretion studies or 50 islets/column for 
perifusion.  Perifusion studies were carried out as previously described (200).  For static culture, 
islet batches were incubated 2 h in KRBH buffer (10 mM HEPES pH 7.4, 134 mM NaCl, 5 mM 
NaHCO3, 4.8 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4 containing 0.5 mg/ml 
BSA) supplemented with 2.8 mM glucose, followed by 1 h incubation in either 2.8 mM or 16.7 
mM glucose.  Insulin secreted into the buffer and insulin content in the corresponding islet lysates 
was quantified by Rat Insulin RIA (Millipore). 
 
3.2.9 Statistical Analysis 
All quantitated data are expressed as mean ± S.E.  Data were evaluated using Student’s t 
test and considered significant if p < 0.05. 
 
3.3 RESULTS 
 
3.3.1 Syntaxin 4 directly interacts with Gelsolin 
 We first identified Gelsolin as a potential Syntaxin 4-binding partner in an unbiased yeast 
two-hybrid screen (D.C. Thurmond and J.E. Pessin, unpublished results), and subsequently 
validated Gelsolin protein to bind directly to recombinant soluble (lacking the C-terminal 
transmembrane domain) GST-Syntaxin 4 in vitro (Figure 3-1A).  Since both Syntaxin 4 and 
Gelsolin are required for glucose-stimulated insulin exocytosis (39, 96), the presence of full-
length endogenous Syntaxin 4-Gelsolin complexes was subsequently investigated, and revealed 
to exist in MIN6 beta cell lysates (Figure 3-1B).  Notably, these complexes were found to rapidly 
and transiently dissociate in response to acute 5 min glucose stimulation.  Following 30 min 
glucose stimulation, Syntaxin 4-Gelsolin complex abundance resumed to ~50% that detected 
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under basal conditions.  Changes in complex formation were independent of changes in Syntaxin 
4 or Gelsolin protein abundances in cell lysates. 
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Figure 3-1.  Syntaxin 4 and Gelsolin directly interact and form complexes in MIN6 beta cells that 
are sensitive to glucose stimulation.  A)  Recombinant Gelsolin was combined with either GST or 
GST-Syn4 (1-273) linked to sepharose beads for 2 h incubation at 4
°
C.  Beads were pelleted and 
extensively washed, with eluates subjected to 10% SDS-PAGE for immunoblot detection (IB) of 
Gelsolin.  Ponceau staining served as control for GST protein loading.  Data are representative of at 
least three independent experiments using two different batches of protein.  B)  MIN6 cells were pre-
incubated in MKRBB for 2 h and stimulated with 20 mM glucose for 5, 15 or 30 min.  Cleared 
detergent cell lysates were prepared and used in Syn4 immunoprecipitation (IP) reactions.  
Immunoprecipitates were resolved on 10% SDS-PAGE and proteins were transferred to PVDF for 
immunoblot detection (IB) of Syn4 and Gelsolin.  Protein abundances in starting input lysates (100 µg) 
were confirmed on a separate gel.  Data are representative of at least three independent co-
immunoprecipitation studies.  Syn4, Syntaxin 4. 
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Given the novelty of this interaction, we next sought to identify the minimal region of 
Syntaxin 4 required to confer direct binding to Gelsolin.  Syntaxin 4 truncations fused C-
terminally to GST were analyzed using in vitro binding studies with recombinant Gelsolin.  As 
depicted in the schematic of Figure 3-2A, Syntaxin 4 protein is composed of three N-terminal 
alpha-helical domains which, based upon comparison with the X-ray crystal structure of family 
member Syntaxin 1A, pack together to comprise a coiled-coil bundle, and are linked to the C-
terminal alpha-helical SNARE domain known to be operational in binding SNARE proteins 
(202).  Elimination of all but the N-terminal most Ha (residues 1-70) domain failed to ablate 
binding to Gelsolin, including the Hb (residues 71-112) region previously shown to be required to 
confer Syntaxin 4 binding to F-actin (64) (Figure 3-2B).  To evaluate this binding event in a 
mammalian cell expression system, CHO-K1 cells were electroporated to express Flag-tagged 
Gelsolin with truncated GFP-Syntaxin 4 fusion proteins (GFP-39-112 and GFP-1-70), and 
detergent solubilized cell lysates were prepared for co-immunoprecipitation analyses.  Indeed, 
anti-Flag (Gelsolin) immunoprecipitation co-precipitated with both truncated forms of Syntaxin 4 
(Figure 3-2C).  Following this, the far N-terminal residues 1-38 were removed to isolate the Ha 
domain, GFP-39-70, which was sufficient to confer binding to Flag-tagged Gelsolin (Figure 3-
2D).  Despite efforts to test for necessity of the Ha domain, deletion of the Ha from either GST- 
or GFP-fusion protein rendered proteins too unstable to study.  Regardless, the ability of this Ha 
domain to confer binding to Gelsolin distinguishes its interaction with Syntaxin 4 from that of F-
actin, since Ha alone failed to confer Syntaxin 4 binding to F-actin (64).  Importantly, this is the 
first demonstration of the Ha domain conferring stable binding with any of the known Syntaxin 4 
binding partners. 
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Figure 3-2.  Residues 39-70 of Syntaxin 4 are sufficient to confer Syntaxin 4-Gelsolin binding.  A)  
Depiction of the multiple helical domains of the Syn4 protein.  The N-terminal helical domains are 
denoted as Ha, Hb, and Hc; the C-terminal H3 helix is the SNARE domain, followed by the 
transmembrane domain (TM).  B)  In vitro binding reactions containing recombinant Gelsolin protein 
plus either GST or GST-Syn4 truncation proteins linked to beads were performed as described in Figure 
3-1, and proteins resolved by 10% SDS-PAGE for immunoblotting (IB).  Ponceau S staining shows the 
presence of the GST proteins in each reaction.  Data are representative of two independent experiments.  
C)  CHO-K1 cells were co-electroporated with pEGFP or pEGFP-Syn4(39-112) and -(1-70) or D)  
pEGFP-Syn4(39-70) plasmids along with pIRES-Gelsolin-Flag DNA, and 48 h later detergent lysates 
were prepared for immunoprecipitation (IP) with anti-Flag antibody.  Immunoprecipitates were 
subjected to 10% SDS-PAGE for immunoblot detection (IB) of GFP and Flag (Gelsolin).  Input lysates 
(50 μg) demonstrate expression and migration of each protein.  Vertical lines denote splicing of lanes 
from within the same gel.  Data are representative of three independent immunoprecipitation 
experiments. 
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3.3.2 Competitive inhibition of endogenous Syntaxin 4-Gelsolin complexes 
Since there are reported effects of apoptosis and compensatory cytoskeletal effects 
associated with Gelsolin knockdown/depletion approaches (152, 243), we opted to use the Ha-
domain peptide (GFP-39-70) as a competitive inhibitor in effort to selectively target the Syntaxin 
4-Gelsolin complex to evaluate its function in insulin exocytosis.  In addition to the unusual 
ability of the Syntaxin 4 Ha domain to confer binding to Gelsolin, as opposed to how Syntaxin 4 
binds other partners, the Ha domain (residues 39-70) carries the least identity of all its helical 
domains (< 35%) to Syntaxin 1A.  Using lysates prepared from MIN6 beta cells expressing the 
GFP-39-70 protein, anti-Syntaxin 4 immunoprecipitation reactions resulted in attenuated co-
precipitation of Gelsolin under basal (unstimulated) conditions, compared to reactions from 
control GFP; a scrambled (GFP-Scr) peptide, designed to retain helical structure (http://npsa-
pbil.ibcp.fr), was without effect (Figure 3-3A).  Having established specificity of the GFP-39-70 
peptide upon Syntaxin 4-Gelsolin complexes, we next evaluated effects following an acute 5 min 
glucose stimulation.  GFP expressing cells showed reduced interaction of endogenous Syntaxin 4-
Gelsolin complexes in GFP expressing cells, similar to that of complexes shown in Figure 3-1B, 
however glucose stimulation of GFP-39-70 expressing cells failed to further dissociate the 
endogenous complex (Figure 3-3B, i).  As we have previously shown that F-actin, but not G-
actin, interacts with Syntaxin 4 in beta cells in a glucose-sensitive manner, and can directly 
interact with Syntaxin 4 in vitro (64), we questioned whether Gelsolin was coupled to this 
interaction.  Coordinate with this, F-actin association with Syntaxin 4 in the presence of the GFP-
39-70 peptide was diminished in unstimulated cell lysates, relative to GFP alone (Figure 3-3B, ii).  
Moreover, pharmacologically-induced actin depolymerization using Latrunculin B (LAT) caused 
dissociation of both actin and Gelsolin from Syntaxin 4 (Figure 3-3C). 
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Figure 3-3.  GFP-39-70 disrupts endogenous Syn4-Gelsolin complexes.  A)  MIN6 cells transfected 
to express GFP, GFP-39-70, or GFP-Scr (scrambled peptide) were preincubated in MKRBB for 2h and 
resultant lysates used for anti-Syn4 immunoprecipitation (IP).  Coprecipitated proteins were resolved on 
10% SDS-PAGE for immunoblot detection (IB).  Data represent at least three independent co-
immunoprecipitation experiments.  B)  MIN6 cells transfected to express either GFP or GFP-39-70 
proteins were pre-incubated and stimulated with 20 mM glucose for 5 min; lysates were used in IP 
reactions as detailed in part A above.  Band intensities of actin and Gelsolin association with Syn4 were 
quantitated and expressed as the ratio of Gelsolin (Gsn) (i) and actin (ii) to Syn4 (normalized, basal 
ratio = 1 for each experiment).  Bars represent the mean ± S.E. of the three independent experiments 
(*p < 0.05, versus unstimulated GFP).  C)  MIN6 cells were treated with vehicle (DMSO) or 10 µM 
latrunculin B (LAT) for 2 h in MKRBB and resultant cell lysates used for IP as described in parts A and 
B above in three independent experiments.  Protein abundances in starting input lysates (100 µg) were 
confirmed on a separate gel.  Vertical lines denote splicing of lanes from within the same gel. 
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Since Gelsolin knockdown in MIN6B1 cells exerted global effects upon F-actin 
remodeling, we investigated this as a potential explanation for the GFP-39-70-induced alterations 
to Syntaxin 4 binding.  We first determined that selective attenuation of Syntaxin 4-Gelsolin 
binding under basal conditions was not attributable to differential GFP-39-70 subcellular 
localization, as its principally cytosolic localization was similar to that of GFP, as visualized by 
confocal microscopy (Figure 3-4, panels 1-4).  However, unstimulated GFP-39-70 expressing 
cells contained contiguous cortical F-actin (red, rhodamine-phalloidin staining) similar to that of 
neighboring untransfected cells and of GFP control cells (Figure 3-4, panels 5-6, 9-10).  
Moreover, GFP and GFP-39-70 expressing cells all showed the expected acute glucose-induced 
actin remodeling, as determined by disruption of the contiguous cortical F-actin rim encircling 
each cell (Figure 3-4, panels 7-8, 11-12).  These data indicated that the GFP-39-70 peptide 
sufficed as a competitive inhibitor of endogenous Syntaxin 4-Gelsolin complexes present in 
unstimulated MIN6 beta cells, and did so without inducing global changes in cortical F-actin 
structure. 
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Figure 3-4.  GFP-39-70 does not disrupt normal glucose-induced actin remodeling.  MIN6 cells 
were plated on glass coverslips and transfected to express GFP or GFP-39-70 proteins (green) were pre-
incubated in MKRBB for 2 h and left unstimulated (top panels 1-2, 5-6, 9-10) or stimulated with 20 
mM glucose for 5 min (bottom panels 3-4, 7-8, 11-12).  Cells were fixed, permeabilized and cortical F-
actin staining detected by Rhodamine-Phalloidin staining (red).  Cells in clusters containing both non- 
and GFP-transfected cells were imaged at the midplane of the cluster by single channel scanning 
confocal microscopy to determine subcellular distribution of the GFP proteins (panels 1-4) and F-actin 
remodeling (panels 5-8).  Merged GFP and F-actin images are shown in panels 9-12 to permit 
comparisons between non-transfected and transfected cells.  Scale bar, 10 µm.  Data shown are 
representative of three independent sets of experiments. 
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3.3.3 Syntaxin 4-Gelsolin complexes are required to clamp unsolicited 
insulin exocytosis events 
 The competitive peptide was subsequently used to determine the functional ramifications 
of disrupting Syntaxin 4-Gelsolin complexes upon insulin secretion from isolated islets and MIN6 
cells.  To ensure thorough and efficient expression of the peptide across cell populations for these 
studies, an adenovirus encoding GFP-39-70 (GFP-39-70-Ad) was generated and validated to 
exert dissociating actions upon endogenous Syntaxin 4-Gelsolin complexes akin to that of the 
plasmid-based delivery system (Figure 3-5).  Subsequently, islets isolated from wild-type 
C57BL/6J mice were transduced with GFP-39-70 or GFP adenoviruses and protein expression 
confirmed (Figure 3-6A), albeit GFP-39-70 expression was consistently lower than that of GFP.  
Islet perifusion experiments were initiated to examine effects of GFP-39-70 expression upon 
basal and phasic insulin release.  GFP-39-70 expressing islets released ~4-fold more insulin under 
basal (2.8 mM glucose) conditions (Figure 3-6B), and first phase secretion appeared to be slightly 
impaired in GFP-39-70 expressing islets (GFP-39-70 peaked 3-fold above basal, GFP peaked 10-
fold above basal).  However, defective basal secretion impeded reliability of area under the curve 
analysis to quantify phasic differences.  We next employed a short term static incubation 
approach as a means to quantify acute/first phase secretion using glucose or KCl secretagogues.  
Again, basal elevation in GFP-39-70 expressing cells was fully recapitulated in the static culture 
system, yet short term stimulated secretions were highly erratic and thwarted efforts to discern 
significant first phase differences (Figure 3-6C).  However, this rise in basal secretion in GFP-39-
70 islets nearly abolished the overall stimulatory responses compared with those of GFP 
expressing islets (SI, stimulation index=glucose-stimulated/basal secretion) (Figure 3-6D).  
Differences in secretion were not due to alterations in insulin content (Figure 3-6E).  No 
significant differences in long-term glucose-stimulated insulin secretion (1 h) or associated 
insulin content were noted between GFP and GFP-39-70 expressing islets (Figure 3-7A and B).  
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These data suggested that dissociation of endogenous Syntaxin 4-Gelsolin complexes under basal 
conditions permitted or otherwise prompted inappropriate insulin release. 
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Figure 3-5.  Adenoviral expression of GFP-39-70 results in disruption of endogenous Syn4-
Gelsolin complexes in unstimulated beta cells.  MIN6 cells were transduced to express either GFP or 
GFP-39-70, and following a 48 h incubation, were subjected to a 2 h preincubation in MKRBB and left 
unstimulated prior to harvest for preparation of cleared detergent lysates.  Lysates were used in Syn4 
immunoprecipitation (IP) reactions, and coprecipitated proteins were resolved on 10% SDS-PAGE for 
immunoblot detection (IB) of Syn4, Gelsolin, and GFP.  Data are representative of two independent 
experiments. 
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Figure 3-6.  Disruption of Syn4-Gelsolin complexes elevates basal insulin secretion from isolated 
mouse islets.  Freshly isolated mouse islets were immediately transduced with GFP or GFP-39-70 
adenovirus, and following 48 h incubation GFP-positive islets were handpicked under a fluorescence 
microscope for immunoblot analysis (A), for perifusion analysis (B), and for static culture studies (C).  
Perifusion entailed use of 50 GFP positive islets per column with GFP and GFP-39-70 expressing islet 
columns run in parallel; islets were perifused with low glucose (2.8 mM) followed by high glucose 
(16.7 mM) to capture first phase release.  Static secretion reactions contained 10 GFP positive 
islets/tube, and were incubated in low glucose (2.8 mM) KRBH for 2 h and buffer collected for 
quantitation of basal insulin secretion.  Buffers containing stimulatory levels of glucose (16.7 mM) or 
KCl (35 mM) were added to the islets for 10 min, followed by collection for insulin quantitation.  
Insulin content in the remaining islets was also determined and used to normalize insulin secretion data; 
*p < 0.001, versus GFP.  D)  Stimulation index was calculated using the values from (C) (SI = 
stimulated insulin release/basal insulin release).  E)  Insulin content was similar between transduced 
islet groups.  Data represent the mean ± S.E. of three independent islet isolation experiments; *p < 
0.05, versus GFP. 
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Figure 3-7.  Adenoviral expression of GFP-39-70 increases basal insulin release from islet beta 
cells.  A)  Mouse islets transduced to express GFP or GFP-39-70 were assessed in static culture 
experiments for insulin release under basal (2.8 mM) or long-term glucose stimulated (20 mM for 1 h) 
conditions.  Secretion data were normalized for insulin content in corresponding islets; B)  insulin 
content was similar between transduced islet groups.  Data represent the average ± S.E. of three 
independent islet batches; *p<0.05 versus unstimulated GFP islets. 
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 Loss of clamping of basal insulin release could result from a direct effect upon Syntaxin 
4 activation, or possibly an indirect effect of aberrant Cdc42 signaling, as has been found to occur 
in other cases of dysregulated basal insulin secretion (77, 210).  To test for alterations in Syntaxin 
4 activation, lysates prepared from MIN6 beta cells transduced to express GFP or GFP-39-70 
protein were combined with recombinant GST-VAMP2 (soluble, TM domain deleted) protein, 
linked to sepharose beads, as a means to selectively precipitate open conformation Syntaxin 4 as 
described previously (64, 210).  It is expected that opening increases accessibility of Syntaxin 4 
to enhance granule docking to promote granule fusion and insulin release.  While GFP expressing 
cells exhibited a low level of basal activation and responded to acute glucose stimulation (5 min) 
with the traditional ~2-fold increase in Syntaxin 4 activation, GFP-39-70 expressing cells showed 
significantly elevated basal Syntaxin 4 activation, with no further responsiveness to glucose 
(Figure 3-8A).  These differences were not a consequence of differential Syntaxin 4 protein 
expression, or between GFP and GFP-39-70 in the starting lysates (Figure 3-8B).  Further 
implicating Syntaxin 4 activation as a mechanism to explain elevated basal secretion, Cdc42 
signaling was unaffected by the GFP-39-70 peptide, as gauged by normal activation 
(phosphorylation) levels of the immediate downstream Cdc42 effector protein PAK1 under basal 
conditions (Figure 3-8C). 
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Figure 3-8.  Disruption of Syn4-Gelsolin complexes triggers Syn4 activation in the absence of 
secretagogue stimulation.  A)  MIN6 cells transduced to express either GFP or GFP-39-70 proteins 
were pre-incubated in MKRBB for 2 h and left unstimulated or stimulated with 20 mM glucose for 5 
min to generate cleared detergent cell lysates for use in GST-VAMP2 interaction assays.  Lysate 
protein (2-3 mg) was combined with GST-VAMP2 (soluble, TM domain deleted) bound to glutathione 
sepharose beads, incubated for 2 h and precipitated proteins resolved on 10% SDS-PAGE for 
immunoblot detection (IB) of Syn4 and GST.  Band intensities of Syn4 association with GST-VAMP2 
were quantitated and the ratio of Syn4 to GST-VAMP2 determined (normalized to unstimulated GFP-
Ad = 1 in each experiment); *p < 0.05, versus unstimulated GFP.  B)  Immunoblot to demonstrate the 
relative expression of GFP and GFP-39-70 proteins in the starting lysates used in GST-VAMP2 
interaction assays.  C)  Basal PAK1 phosphorylation was evaluated by immunoblotting lysates prepared 
from transduced and unstimulated MIN6 cells.  The marker indicates the upper phospho-PAK1 band; 
lower band is non-specific.  Blots were subsequently stripped and reprobed for total PAK1 protein.  
Images are representative of three independent sets of transduced cell lysates. 
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3.3.4 Syntaxin 4-Gelsolin complexes and the KATP-channel-dependent/triggering pathway 
in MIN6 beta cells 
 Islets are composed of multiple cell types.  To ascertain whether erratic short-term insulin 
secretion outcomes from islet studies were due to possible effects of non-insulin secreting cell 
types within islets, secretion studies were performed in the clonal MIN6 beta cell system.  Mouse 
clonal MIN6 cells are considered to have similar insulin content and glucose-stimulatory response 
similar to that of normal islets, where normal responses occur at 16-20 mM glucose (244).  As 
observed in mouse islets, expression of the GFP-39-70 but not the GFP-Scr peptide in MIN6 cells 
induced elevation of basal secretion in the absence of secretagogue (Figure 3-9A and 9B), though 
to a lesser extent than observed in whole islets.  Similar to islets, prolonged glucose stimulation 
failed to unveil significant differences in insulin release between GFP and GFP-39-70 expressing 
cells (data not shown).  By contrast, acute stimulation (10 min) with either glucose or KCl in 
GFP-39-70-expressing cells elicited small but significant ~20% attenuations of acute (10 min) 
stimulus induced secretion (Figure 9C): 20 mM glucose (205 ± 22 and 169 ± 20 ng/mg protein 
for GFP versus GFP-39-70, respectively), and with 35 mM KCl (499 ± 48 and 410 ± 24 ng/mg 
protein for GFP versus GFP-39-70, respectively).  The combined impairments in basal and 
secretagogue-stimulated secretion culminated in significant losses in stimulation index (Figure 3-
9D), and were not due to GFP-39-70-induced beta cell apoptosis, as evaluated by caspase-3 
cleavage (Figure 3-9E). 
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Figure 3-9.  Disruption of Syn4-Gelsolin complexes impairs insulin secretion from MIN6 beta 
cells.  A)  MIN6 cells adenovirally transduced to express either GFP or GFP-39-70 proteins were pre-
incubated in MKRBB for 2 h and left unstimulated to determine the insulin secretion stimulation index 
(SI = stimulated insulin release/basal insulin release).  B)  MIN6 cells electroporated to express the 
GFP-39-70 or the GFP-Scr peptide in MIN6 cells were evaluated for effects upon basal secretion.  Data 
represent the average ± S.D. of two independent sets of electroporated cells.  C)  MIN6 cells 
adenovirally transduced to express either GFP or GFP-39-70 were preincubated in MKRBB for 2 h and 
stimulated with 20 mM glucose or 35 mM KCl for only 10 min.  Insulin secreted into the buffer was 
quantified by RIA and normalized for total protein content in corresponding cell lysates.  Data represent 
the mean ± S.E. of at least three independent experiments, *p<0.05, versus GFP.  D)  Data from C 
represented as stimulation index.  Data in C, and D represent the mean ± S.E. of at least three 
independent islet batches; * p < 0.05, versus GFP.  E)  Caspase cleavage was assessed in MIN6 cells 
transduced to express GFP or GFP-39-70 by immunoblotting (IB) for caspase-3, which recognizes the 
35 kDa inactive protein and the 19 kDa cleaved activated form.  Treatment for 16 h with 0.5 µM 
thapsigargin (TG) to induce apoptosis served as a positive control.  The GFP immunoblot shows 
expression of GFP and GFP-39-70 (NT, not transduced) and tubulin immunoblot used as a loading 
control.  Data are representative of two independent experiments. 
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Another method used to assess the phases of glucose-stimulation is by the diazoxide 
paradigm.  This pharmacological paradigm is based upon the premise that the first phase release 
is due to ATP-sensitive potassium channel (KATP)-dependent triggering, while the second phase is 
regulated by KATP channel-independent amplifying effects (2, 245-247).  By subjecting MIN6 
beta cells to depolarizing KCl concentrations in the presence of the KATP channel opener 
diazoxide, low glucose simulates triggering, and high glucose simulates amplification (44).  
Using this paradigm, GFP-39-70-expressing cells showed ~30% decrease in the KCl-stimulated 
triggering of insulin secretion compared to GFP-expressing controls (Figure 3-10A).  Diazoxide 
action was verified by abolishment of secretion from cells treated with diazoxide alone or in 
combination with glucose in the absence of depolarizing KCl concentrations (data not shown).  
The GFP-expressing cells exhibited the amplifying response, with ~3-fold more insulin release 
upon stimulation with glucose, validating responsiveness of the cells (44, 47).  However, the 
stimulation index of the amplification effect between GFP- and GFP-39-70-expressing cells was 
similar (Figure 3-10A, inset graph).  This suggested that artificial disruption of the Syntaxin 4-
Gelsolin complex by the GFP-39-70 peptide may have compromised triggering.  Efforts to use 
this paradigm in adenovirally transduced islets failed however, as a combination of these islets 
and diazoxide treatment dramatically reduced insulin content (data not shown). 
We next determined whether triggering steps impacted the Syntaxin 4-Gelsolin complex 
dissociation.  The triggering pathway is defined as that involving closure of KATP channels, 
membrane depolarization, opening of voltage-dependent calcium channels, calcium influx and 
rise in [Ca
2+
]c, and activation of the exocytotic machinery (248).  Testing these steps, acute KCl 
stimulation dissociated Syntaxin 4-Gelsolin complexes (Figure 3-10B).  Consistent with this, 
treatment with nifedipine, which blocks calcium influx through the beta cell’s voltage dependent 
calcium channels, blocked glucose-induced dissociation of endogenous Syntaxin 4-Gelsolin 
complexes (Figure 3-10C).  However, Fura-2 calcium imaging experiments revealed no decrease 
in KCl-stimulated increases in [Ca
2+
]c in GFP-39-70-Ad expressing cells versus GFP cells (Figure 
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3-10D), suggesting that the GFP-39-70 peptide does not disrupt Syntaxin 4-Gelsolin complexes 
and acute insulin secretion via disrupting calcium influx/elevation of [Ca
2+
]c per se.  Taken 
together with the abnormal activation of SNARE machinery (Syntaxin 4) induced by the GFP-39-
70 peptide data of Figure 8, these data support the conclusion that a stimulatory defect induced by 
the GFP-39-70 peptide was downstream of calcium influx/elevated [Ca
2+
]c, perhaps at steps of 
Gelsolin activation and/or SNARE-mediated granule docking/fusion.  Indeed, the calcium 
sensitivity of Gelsolin activation is ~300-1000 nM, consistent with that of insulin exocytosis 
(147, 249). 
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Figure 3-10.  Disruption of Syn4-Gelsolin complexes impairs the triggering pathway.  A)  Effects 
of GFP-39-70 were evaluated by the diazoxide paradigm.  MIN6 cells transduced to express GFP or 
GFP-39-70 proteins were incubated with 250 μM diazoxide and 35 mM KCl, followed by addition of 
20 mM glucose for 30 min and upon insulin secretion quantified.  Insulin released was normalized for 
corresponding cellular protein content (ng insulin/mg protein).  Inset, stimulation index = insulin 
release under diazoxide+KCl+glucose treatment / insulin release under diazoxide+KCl treatment alone 
(black bar=GFP, open bar=GFP-39-70).  Data represent the mean ± S.E. of at least three independent 
islet batches; * p < 0.05, versus GFP.  B)  MIN6 cells preincubated in MKRBB were stimulated 5 min 
with KCl (50 mM) and resultant cell lysates used for Syn4 IP as described in Figure 3-1B.  Data are 
representative of five independent experiments.  C)  MIN6 cells treated with vehicle (DMSO) or 
nifedipine for 1 h during preincubation in MKRBB were acutely stimulated with glucose (20 mM) for 5 
min, in the continued presence of nifedipine/DMSO, and resultant cell lysates used in anti-Syn4 
immunoprecipitation reactions.  Protein abundances in starting input lysates (100 µg) were confirmed 
on a separate gel.  Data are representative of three independent experiments.  D)  MIN6 cells on glass 
coverslips transduced to express GFP or GFP-39-70 proteins were pre-incubated in MKRBB 
supplemented with 2 mM glucose for 2 h followed by loading with Fura-2/AM.  Cells were subjected to 
perfusion for 300 sec under low KCl (5 mM) conditions and switched to buffer containing stimulatory 
KCl (35 mM) for an additional 300 sec to evaluate calcium influx.  Each 340/380 ratio trace was 
normalized to the initial basal value (F0) of the respective trace to yield ΔF/F0. 
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3.4 DISCUSSION 
 
In this report we demonstrate the existence of a novel interaction between the SNARE 
protein Syntaxin 4 and the F-actin-severing/capping protein Gelsolin, and that this interaction was 
susceptible to disruption upon glucose- and KCl-stimulation in beta cells.  Introduction of a 
competitive inhibitory peptide, GFP-39-70, into pancreatic beta cells disrupted endogenous 
Syntaxin 4-Gelsolin complexes under basal conditions, mimicking the action of secretagogue-
stimulation, providing strong evidence for a crucial functional role for this complex in clamping 
unsolicited basal insulin secretion.  Mechanistically, disruption of Syntaxin 4-Gelsolin complexes 
spurred inappropriate activation of Syntaxin 4 under basal conditions, consistent with the concept 
of Gelsolin binding to Syntaxin 4 to mitigate unsolicited Syntaxin 4-mediated granule 
docking/fusion events.  In addition to a role in the clamping mechanism, data gained from MIN6 
cells suggests that Syntaxin 4-Gelsolin complexes may also participate in the calcium- and KATP-
channel dependent/triggering mechanism of insulin release, although further studies will be 
required to substantiate this possibility in primary cells.  Such a dual action of Syntaxin 4-
Gelsolin complexes would be consistent with very recent work showing that actin filaments both 
prevent and augment the exocytosis of a single regulated secretory granule (250). 
Gelsolin is a known calcium-activated F-actin severing/capping protein consisting of six 
homologous domains, each of which contain calcium binding sites that contribute to calcium-
induced alterations to Gelsolin’s conformation and activity (145, 147, 251, 252).  Since Gelsolin 
is activated by calcium at levels observed in KCl- and glucose-stimulated beta cells (147, 249), it 
could be speculated that Gelsolin participates within calcium microdomains for F-actin clearance 
at active sites of exocytosis.  If so, one explanation for the effect of the GFP-39-70 peptide is that 
it displaced Syntaxin 4 from a calcium microdomain.  However, Syntaxin 4 remains at the PM in 
cells treated with latrunculin B, and moreover, that Syntaxin 4 is activated (64) and presumed to 
be functional given the potentiating effect of latrunculin upon calcium-stimulated insulin release 
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(33).  Regarding Gelsolin’s role at calcium microdomains for actin clearance, this remains 
controversial: Gelsolin knockdown in the MIN6B1 cell line ablated glucose-induced F-actin 
remodeling, but the recent analyses of islets from Gelsolin knockout mice do not show effects 
upon F-actin remodeling (151), and now we also show that the GFP-39-70 peptide fails to impact 
actin remodeling.  The lack of effect of the GFP-39-70 peptide upon actin remodeling under basal 
conditions could be explained by the need for calcium activation of Gelsolin, and that its mere 
dissociation from Syntaxin 4 was insufficient to induce actin remodeling.  Moreover, the absence 
of a refractory response from the cytoskeleton to the competitive peptide, could suggest that 
Gelsolin’s severing activity was unaffected by the peptide.  As such, the GFP-39-70 peptide 
would likely not induce the many and diverse defects associated with Gelsolin knockout or 
knockdown, such as compensatory increases in Rac1 protein, reduced fibroblast motility, 
neurological and immune system defects (98, 243, 253), and did not cause apoptosis as was 
observed in Gelsolin-depleted MIN6B1 cells (152).  Because the degree of change in stimulated 
insulin secretion was similar in cells depleted of Gelsolin (36%) and those expressing the GFP-
39-70 peptide (~30%), the implication is that Gelsolin’s mechanism of action in glucose-
stimulated insulin secretion might be through its interaction with Syntaxin 4.  This may be further 
impacted by phosphoinositide binding and regulation of Gelsolin (254-256).  The lack of a larger 
deficit in insulin secretion could be due to compensation by a closely related family member, 
Scinderin, which shows expression only in adrenal chromaffin cells, kidney and intestinal cells 
(154), and pancreatic beta cells (data not shown).  Scinderin and Gelsolin share more than 60% 
sequence identity, and a Scinderin-derived actin-binding peptide inhibited Ca
2+
-dependent 
exocytosis without affecting the whole-cell Ca
2+
 current, by 61% in mouse pancreatic beta-cells 
(159).  Thus, the potential remains that Gelsolin and Scinderin work in an additive manner, 
perhaps via Syntaxin 4; due to Scinderin’s more limited expression profile, Syntaxin 4-Scinderin 
complexes in the beta cell could present a means to selectively manipulate insulin release. 
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Poorly regulated/constitutive and non-secretagogue specific insulin release from an islet beta cell 
is characteristic of an aberration of the regulated exocytosis (SNARE protein) machinery; F-actin, 
which is shown to function both in preventing unsolicited basal exocytosis and in promoting 
secretagogue-induced exocytosis in endothelial cells (250), may also be defective.  Syntaxin 4 
activation appears to be linked to its association with F-actin, which vacillates in the presence of 
secretagogue (64).  As such, one possible reason that the GFP-39-70 peptide disrupted both basal 
and stimulated secretion in the MIN6 cells is that it may have interfered with normal 
activation/deactivation cycling of Syntaxin 4: following fusion, SNARE complexes undergo 
disassembly with t-SNARE proteins deactivated and recycled for subsequent rounds of 
docking/fusion.  Furthermore, residues within the t- and v-SNARE proteins that become surface 
exposed upon conformational changes induced by assembly into the heterotrimeric SNARE core 
complex have been linked directly to calcium triggering of exocytosis from chromaffin cells 
(257).  Since Syntaxin 1A can associate directly with the operative L-type voltage dependent 
calcium channels in beta cells (258, 259), placing SNARE core complex formation at the site of 
calcium entry into the cell, future studies of Syntaxin 4 binding to channels will be required to 
determine if this could also account for GFP-39-70 peptide induced defects.  Alternatively, 
constitutive Syntaxin 4 activation induced by the peptide could have disrupted binding and 
function of SNARE accessory proteins that bind calcium, such as Synaptotagmin 7 and Doc2b, 
both of which function in insulin secretion (201, 260-262).  Nevertheless, despite our utilization 
of multiple and diverse approaches, we were unable to reproducibly detect defects in first 
phase/triggering in GFP-39-70 expressing islets.  One possibility is that the peptide exerted 
effects in non-beta cells of the islet, particularly since Syntaxin 4 and Gelsolin are considered 
ubiquitously expressed proteins, and this generated sufficient ‘noise’ in our systems to negate 
detection of the small expected changes in secretion.  De-regulation of basal secretion in the islets 
was also far more substantial (4-fold) than in MIN6 beta cells, effectively blunting any further 
secretagogue-induced increase in stimulation index.  Notably however, actin filaments prevent 
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hypersecretion as well as promote stimulated secretion (250). Given that changes in actin 
tethering to Syntaxin 4 occur in tandem with Gelsolin, it remains possible that GFP-39-70 has 
impacted this process.  Future studies utilizing real-time imaging of in-cell Syntaxin biosensors 
that distinguish open from closed conformations will be required to determine its cyclic activation 
patterns in primary islet beta cells. 
The Ha domain of Syntaxin 4, in isolation, has not previously been shown to be sufficient 
to confer its binding to any other of Syntaxin 4’s binding partners other than Gelsolin.  Syntaxin 4 
directly interacts with both Gelsolin and F-actin, and Gelsolin directly binds to F-actin, however 
it remains unknown whether the three form a heterotrimeric complex.  The simultaneous 
dissociation of Syntaxin 4 from F-actin and from Gelsolin in response to acute glucose 
stimulation in beta cells might support this concept, although efforts to reciprocally co-
immunoprecipitate the complex from cell lysates, or efforts to capture the complex in vitro, were 
unsuccessful due to technical limitations with available reagents.  As such, the inappropriate 
Syntaxin 4 activation could potentially be caused by the dissociation of F-actin that happens 
alongside disruption of the Syntaxin 4-Gelsolin complex.  Indeed, this is seen using a peptide 
containing the minimal region of Syntaxin 4 that binds F-actin (GFP-39-112), or through global 
F-actin depolymerization using the actin monomer binding agent Latrunculin B (64).  Oddly, 
treatment with Latrunculin failed to also elevate basal insulin secretion, suggesting that there is 
distinction between non-specifically disrupting the entire F-actin cytoskeleton and disrupting 
select protein-protein interactions, as in the case of using GFP-39-70 to disrupt Syntaxin 4-
Gelsolin complexes.  The idea that basal insulin secretion is influenced by the cytoskeleton is 
supported by studies of EphA-Ephrin-A signaling, cell-cell contact and Focal Adhesion Kinase 
(132, 136, 239). 
It is interesting that cells expressing GFP-39-70 and further subjected to acute glucose 
stimulation did not elicit an additive effect upon disruption of Syntaxin 4-Gelsolin complexes, 
such that a contingent of complexes persisted.  This phenomenon was also observed with peptide 
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disruption of F-actin-Syntaxin 4 binding (64).  One possibility is that the peptide is only capable 
of mimicking the action of secretagogue and only disrupts a subset of complexes; some may be 
refractory or inaccessible.  Furthermore, it remains unknown as to whether Syntaxin 4 associates, 
transiently or otherwise, with Gelsolin and/or F-actin during the dynamic process of SNARE 
complex assembly/disassembly; dissociation events may be so transient that it is not possible to 
detect all dissociated in sync.  Although it also remains possible that the peptide is a relatively 
poor competitor, despite our lysate evidence showing it to be abundantly expressed, future studies 
of Syntaxin 4-Gelsolin complex kinetics are required to address issues related to dissociation 
susceptibility.  
In conclusion, we describe the first mechanistic evidence for Gelsolin in regulating the 
exocytosis machinery, via its direct association with the t-SNARE protein Syntaxin 4.  Through 
association with Syntaxin 4, Gelsolin plays a critical role as a clamp on unsolicited Syntaxin 4 
activation and aberrant insulin release in the absence of the appropriate secretagogue signal.  
Calcium may act as the key which unlocks the Gelsolin clamp, as it is known to initiate Gelsolin 
conformational changes.  Once released from Gelsolin, Syntaxin 4 activates and joins other 
SNARE proteins to facilitate granule docking and fusion.  Importantly, elevated basal insulin 
release observed in islets with peptide-induced disruption of Syntaxin 4-Gelsolin complexes 
models the constitutive insulin release observed in pre-diabetic and type 2 diabetic patients, prior 
to onset of beta-cell apoptosis; this may provide new insight into the dysregulation of insulin 
exocytosis in diabetes.  From a broader perspective, Gelsolin and Syntaxin 4 are ubiquitously 
expressed proteins, such that their interaction may represent a more generalized clamping 
mechanism required for maintaining the ‘regulated’ aspect of SNARE-mediated exocytosis. 
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CHAPTER 4.  CONCLUDING REMARKS 
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The objective of this dissertation was to elucidate mechanisms of F-actin remodeling and 
SNARE-mediated insulin secretion in pancreatic beta cells.  My dissertation work encompasses 
the initial glucose-induced activation of the Cdc42-PAK1 pathway which leads to ERK 
activation, the F-actin remodeling process, and finally the effects of glucose and the Cdc42-PAK1 
pathway upon Syntaxin 4 during the final steps of insulin exocytosis.  Here, I will discuss the 
primary issues addressed in each chapter of my dissertation, including how this work impacts the 
field of beta cell biology and other systems, with suggestions towards additional work needed in 
those specific areas.  Additionally, I propose future studies pertaining to F-actin remodeling, 
signal transduction, and SNARE protein regulation in the beta cell.  These studies will be 
required to progress our understanding regarding the mechanisms regulating insulin secretion. 
The role of PAK1 in secretory processes is a largely understudied area.  PAK1 is 
classically known to be involved in cell survival and motility and is an actively researched target 
for anti-cancer therapies (73, 263, 264).  PAK1 has also been hypothesized to be a bridge 
between GTPase signaling and the MAP kinase pathways (87, 175).  Our lab has shown that 
PAK1 is critical during the second phase of insulin secretion from human and mouse pancreatic 
islets and in insulin-stimulated GLUT4 translocation in mouse skeletal muscle (43, 45).  My 
dissertation work supports these observations in beta cells and extends our knowledge beyond 
Cdc42 to show that PAK1 signaling 1) facilitates glucose-induced cortical F-actin remodeling 
through MEK-ERK signaling, 2) mediates MEK-ERK signaling that is important for amplifying 
insulin secretion, 3) is required for the accumulation of VAMP2-bound insulin granules at the 
PM, and 4) regulates Syntaxin-4-F-actin complexes.  I found that PAK1 activation is required for 
MEK phosphorylation in beta cells, which is consistent with reports of PAK1-MEK signaling in 
vitro and in rodent fibroblast cell lines and HEK293 cells and explains why the PAK1 KO mouse 
islets had defective glucose-induced ERK activation (45).  Additionally, PAK1 and ERK 
activation are required for glucose-induced F-actin remodeling, which plays an important role 
regulating glucose-induced insulin secretion.  Indeed, blocking PAK1 activation attenuates a very 
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distal event in the process of insulin granule exocytosis, the transit/retention of VAMP2-bound 
insulin granules at the plasma membrane.  These data contribute to our understanding of why 
PAK1 inhibition selectively reduces the amplification/second phase of glucose-stimulated insulin 
secretion, the phase which is more dependent on granule mobilization.  Finally, PAK1 inhibition 
disrupts Syntaxin 4-F-actin complexes in the basal state without increasing basal insulin 
secretion, which links PAK1 signaling to SNARE-mediated exocytosis for the first time.  It is 
noteworthy that other molecules can also act through PAK1, and Cdc42 may not be the sole 
upstream initiator of PAK1 activity.  For example, recent work suggests that the SAD-A protein 
kinase can activate PAK1 in beta cells (224).  SAD-A has also been implicated in activating 
cAMP-potentiated glucose-stimulated insulin secretion dependent on PAK1, possibly placing 
PAK1 downstream of PKA-dependent signaling. 
The knowledge gained from my studies of PAK1 signaling in the beta cell has significant 
potential to influence research in other fields.  PAK1 signaling is implicated in insulin-stimulated 
GLUT4 translocation (45), GLP-1 secretion from enteroendocrine L cells (229), and neuronal 
physiology (265).  As for islet cell types other than beta cells (alpha cells, delta cells, PP cells), 
investigation into the role of PAK1 in alpha cells is still in its infancy (45).  Glucagon secretion is 
normal in islets from PAK1 knockout mice (45), but further studies in metabolically stressed 
animals (e.g. high-fat diet) or stressed islets ex vivo (e.g. high glucose/palmitate) will be required 
to determine whether PAK1 has any role in alpha cells.  In fact, MEK inhibitors can block 
ghrelin-induced glucagon secretion and ERK phosphorylation in the alpha cell line, alpha-TC1 
(266).  My data point to new and previously unrecognized PAK1 signaling pathways and can 
serve as rationale for considering unorthodox roles for PAK1 in other secretory cell types. 
Back in 2006 it was reported that Gelsolin was involved in glucose-stimulated insulin 
secretion, although the exact mechanisms for this were undefined (96).  My work has added to the 
understanding of Gelsolin function in beta cells.  I showed that Gelsolin interacts with the 
SNARE protein Syntaxin 4, a key regulator of biphasic insulin secretion (39, 143), and that the 
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ability of glucose to target this association in a dynamic manner is important to maintaining 
normal low basal secretion as well as normal glucose stimulated biphasic secretion.  Syntaxin 4 
directly interacts with F-actin and, in response to glucose, Syntaxin 4-F-actin complexes 
dissociate (64, 143).  Disruption of Syntaxin 4-F-actin with a competing peptide or through 
depolymerization of F-actin with latrunculin leads to increased Syntaxin 4 activation and insulin 
secretion, but it was unclear how this occurs (64).  My findings suggest that the binding of 
Gelsolin to Syntaxin 4 regulates Syntaxin 4-F-actin interaction and Syntaxin 4 activation.  PAK1 
also regulates Syntaxin 4-F-actin complexes, but this may not be the case for Syntaxin 4-Gelsolin 
complexes.  Syntaxin 4-Gelsolin complexes respond to calcium influx alone, while calcium influx 
alone cannot activate Cdc42 (43).  It could be speculated that PAK1 activation of Rac1 might 
inactivate Gelsolin at later time points of glucose stimulation (20-30 min).  The possibility 
remains that other F-actin binding proteins also bind to Syntaxin 4 to bridge indirect F-actin 
association, such as alpha-fodrin (160, 161).  In addition, the closest relative of Gelsolin, 
Scinderin (also called Adseverin), interacts with Syntaxin 4 and may play a role similar to 
Gelsolin in the regulation of Syntaxin 4 and insulin secretion (Kalwat and Thurmond, 
unpublished data).  A single study exists on Scinderin in primary beta cells, in which small 
interfering peptide regions of Scinderin were used to block its activity in patch-clamp 
experiments (159).  In that study, blocking Scinderin activity prevents Ca
2+
- and GTP-stimulated 
secretion (159) although further studies are required to validate the effects of more specific 
inhibition of Scinderin via knockdown.  Since Gelsolin and Scinderin have different calcium 
sensitivities, their interaction with Syntaxin 4 may underlie differential responses to varying 
magnitudes of stimulation (158).  The precise mechanisms underlying Gelsolin regulation of 
Syntaxin 4 activation are unclear.  However, since I found that Ca
2+
 influx is both necessary and 
sufficient for Syntaxin 4-Gelsolin dissociation, it is likely that Ca
2+
 signaling is involved in 
Syntaxin 4 activation.  Gelsolin is a Ca
2+
-activated F-actin severing protein, therefore 
investigations using Ca
2+
-binding mutants of Gelsolin (267) will be required to determine 
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whether the effect of Ca
2+
 on Syntaxin 4-Gelsolin is direct or indirect.  My work also pinpointed 
the region of Syntaxin 4 which is sufficient to confer Syntaxin 4 binding to Gelsolin, the Syntaxin 
4 39-70 residue region (Ha helix).  This is a novel interaction to date, although it suggests that 
other syntaxin isoforms may have an unrecognized potential to interact with F-actin binding 
proteins in a manner similar to Gelsolin via this region. 
 
4.1 FUTURE STUDIES 
 
4.1.1 The Cdc42-PAK1 Pathway 
 Small Rho GTPases have been implicated in beta cell biology for the last 15 years (69), 
and even though much research has been done, we still lack knowledge concerning many key 
events which occur in the Cdc42-PAK1-Rac1 pathway in response to glucose.  Such events 
include the identity of the glucose-specific signal that activates Cdc42, the exact effectors of 
PAK1 signaling in the beta cell, and how this pathway links to exocytosis. 
 It is clear that the metabolism of glucose is required for Cdc42 activation, as non-
metabolizable analogs do not cause activation (43).  Studies using various metabolites that can 
enter certain steps of glycolysis (i.e. glyceraldehyde) or the citric acid cycle (i.e. methylpyruvate) 
will be required to determine the exact source of the metabolite(s) which initiate Cdc42 
activation.  It would not be surprising if these metabolites activated certain GEFs for Cdc42 
(βPix) or deactivated certain GDIs (RhoGDI and Cav-1) and GAPs.  As we have recently found, 
βPix is a GEF for Cdc42 in the beta cell and is required for proper Cdc42 activation in response 
to glucose (74), but this does not preclude the existence of additional GEFs that may play a role.  
It has also been found in beta cells during time points preceding Cdc42 activation at 3 min, that 
the Arf6 and ARNO proteins are activated and are required for Cdc42 activation, although the 
Arf6/ARNO pathway is not glucose-specific (75). Therefore the identity of the glucose-specific 
Cdc42 activator is still unclear. 
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 The recent publication suggesting that SAD-A kinase is an upstream activator of PAK1 
(224) brings up the question of whether or not SAD-A activation is dependent on Cdc42 
activation.  The involvement of Cdc42 could be tested using either siRNA-mediated depletion of 
Cdc42 or through the use of a novel Cdc42 small molecule inhibitor called ML-141.  After 
ablation of Cdc42 function in beta cells, SAD-A kinase activation could be assessed by 
immunoblot.  This would be supported by more detailed studies of the time course of SAD-A 
kinase activation in response to stimuli, since a Cdc42-dependent process would be expected to 
occur after 3 min of glucose stimulation.  Preliminary data from our own laboratory suggests 
PAK1 also to be downstream of cAMP-potentiated secretion, since IPA3 treatment disrupts GLP-
1 potentiated secretion, and GLP-1 signaling is known to involve cAMP and PKA signaling 
(Zhanxiang Wang, unpublished data).  If Cdc42-PAK1 is indeed part of the GLP-1/cAMP 
signaling pathway, it would be pertinent to test whether this is through PKA, Epac2, or both using 
analogs of cAMP that specifically activate either PKA or Epac2. 
Linkage between the Cdc42-PAK1 pathway and SNARE-mediated insulin secretion may 
not be an improbable idea.  Indeed, Cdc42 interacts with VAMP-2 and can participate in a tertiary 
complex with VAMP-2 and Syntaxin 1A (86). Additionally, since PAK1 is capable of localizing 
to membranes and can phosphorylate multiple substrates that regulate F-actin dynamics, PAK1 
may regulate F-actin interaction with proteins on the plasma membrane (73).  This notion is 
supported by my results showing that blocking PAK1 activation with IPA3 disrupts the normal 
Syntaxin 4-F-actin interaction (Figure 2-6).  This suggests that PAK1 could indirectly affect 
Syntaxin 4-F-actin complexes through its influence on F-actin dynamics. 
 
4.1.2 The ERK Pathway 
If or how the ERK pathway functions in glucose-stimulated insulin secretion is 
controversial.  Whether ERK plays any acute signaling roles in insulin secretion and/or whether it 
solely mediates its effects through transcriptional activation of key beta cell genes is the crux of 
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the controversy.  It is clear that ERK is activated shortly after stimulation with secretagogues or 
growth factors and that ERK can subsequently translocate to the nucleus to mediate effects on 
transcription (178, 223).  A sizeable portion of active ERK remains in the cytosol as well (178), 
which raises the question about what cytosolic substrates ERK may act on in beta cells.  Recently, 
a screen in NIH 3T3-L1 fibroblasts yielded 67 novel ERK2 substrates (268), including two Cdc42 
effector proteins (CDC42EP1 and 2) and myosin IXb.  In another study, ERK was shown to 
activate MLCK (171).  Since many ERK substrates are linked to F-actin dynamics, future 
investigations should assess whether these substrates have roles in the beta cell.  Discrepancies 
between studies regarding the impact of ERK inhibition on insulin secretion may stem from 
differences in cell lines, islet sources, and the duration and concentrations of glucose and/or 
MEK-specific inhibitors used.  These variations lead to cases where inhibition of ERK activation 
either showed no effect on secretion (178), versus where it depresses secretion but to differing 
degrees of severity (96, 180).  Further, conclusions based upon knockdown of ERK levels in beta 
cells must be interpreted carefully as knockdown usually requires 48 hours, leaving open the 
possibility for transcriptional changes (95). In fact, inhibition of ERK for 36 hours was shown to 
prevent glucose-induced insulin gene transcription in MIN6 cells (269).  Future work will require 
short-term (1-2hr) MEK inhibition to ascertain the need for acute glucose-dependent ERK 
activation in Syntaxin 4-F-actin dynamics and SNARE complex formation. 
 
4.1.3 Regulation of F-actin Dynamics 
There is a paucity of knowledge about F-actin binding proteins downstream of Cdc42 or 
PAK1 that may be important in glucose-stimulated F-actin remodeling and insulin secretion.  In 
addition to Gelsolin, its closely related family member, Scinderin, may have a role in the beta 
cell.  Since Scinderin has a critical role distinct from Gelsolin in adrenal chromaffin cell secretion 
(126, 270) and is capable of binding to Syntaxin 4 in beta cells, the possibility exists that 
Scinderin is a regulator of insulin secretion and SNARE-F-actin association.  The use of 
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knockdown approaches to reduce levels Scinderin alone or both Scinderin and Gelsolin will 
likely be required to determine the relative contribution of Scinderin to insulin secretion and 
glucose-induced F-actin remodeling in beta cells.  Scinderin would be an intriguing target for 
pharmacological intervention of insulin secretion since its expression is limited to neuroendocrine 
and intestinal cells as opposed to Gelsolin which is ubiquitously expressed (154, 156). 
While it is true that Profilin and Arp2/3 are potential candidates for glucose-induced F-
actin remodeling, during my studies I chose to first investigate the Cdc42-PAK1 pathway and 
potential downstream PAK1 targets.  The evidence that PAK1 is both crucial for second phase 
insulin secretion and downstream of Cdc42 points supports this line of research.  While Arp2/3 is 
downstream of Cdc42, it is also possible that PAK1 can signal to Arp2/3 (93).  In light of my 
recent data regarding the ~30% deficit in GSIS from MIN6 cells where ERK activation is 
completely blocked, it makes sense to investigate alternative PAK1 signaling pathways that may 
account for the remainder of GSIS not accounted for by PAK1-MEK-ERK signaling. 
 With regard to Profilin, not much information is available pertaining to its role in 
stimulated exocytosis, but it has been shown to have a regulatory role in synaptic vesicle 
exocytosis through actin polymerization (271).  In eukaryotic cells, Profilin promotes the 
polymerization of actin by binding G-actin and promoting exchange of ADP for ATP (144) to 
ultimately deliver actin monomers to the barbed end of growing actin filaments.  Inactivation of 
Profilin can be mediated via its binding to PIP and PIP2, and in this way its regulation may be 
linked to membrane processes (144).  Maintenance of an intact cortical F-actin cytoskeleton in 
the basal state is critical for regulation of stimulated insulin secretion, since treatment of islets 
with latrunculin causes massively unregulated secretion in response to glucose while leaving 
basal secretion unaffected (33, 64, 130).  In some instances, glucose has been shown to elicit the 
net polymerization of F-actin in islets, implicating a need for regulatory proteins like Profilin 
(272) .  Profilin interacts with Arp2 of the Arp2/3 complex and has been suggested to interact 
with WASP proteins (144) , and both Arp2/3 and WASP are currently being investigated for a 
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role in beta cell F-actin remodeling (85).  Studies of proteins like Profilin will thus be required to 
expand our understanding of how glucose-induced F-actin remodeling is mediated and how it 
ultimately regulates insulin granule exocytosis. 
Of the Rho family GTPases, Cdc42 and Rac1 were shown to be the major forms 
operative in GSIS (69); RhoA inhibition was less impactful upon GSIS in the hamster insulinoma 
cell line HIT.  Quite unexpectedly, during the course of my studies on Gelsolin and PAK1 in 
GSIS, another group demonstrated that RhoA and one of its key effectors Rho-associated kinase 
(ROCK) did indeed impact GSIS (70, 273), but as negative regulators of insulin secretion, as their 
pharmacological inhibition enhanced insulin secretion in sorted primary rat beta cells (70).  The 
discrepancies between these findings could have to do with primary cell versus cell line 
differences and in the duration of treatment with the RhoA inhibitor (24 h in the former, 48 h in 
the latter).  Studies in secretion from neutrophils show that RhoA has a role on the secretory 
granule to block localized actin depolymerization or alternatively facilitate F-actin polymerization 
(99, 274).  Since ROCK is known to cause MLC activation through inhibiting myosin light chain 
phosphatase (275) and since RhoA signaling and Cdc42/Rac1 signaling have been reported to 
oppose each other (276-278), inhibition of the RhoA-ROCK pathway may be worthy of pursuit 
for new therapies for type 2 diabetes.  Indeed, multiple inhibitors of ROCK have been developed 
and seem to be beneficial in beta cell lines (279-281), although the potential effects on the beta 
cell in vivo remain to be determined.  In addition, the opposing roles of RhoA and Cdc42/Rac1 
need to be verified in beta cells, therefore future studies are required to fully understand how 
RhoA might intertwine with the Cdc42-PAK1 pathway and F-actin remodeling in beta cells. 
 
4.1.4 Regulation of Syntaxin 4 
Exactly how Syntaxin 4 is activated to form the tertiary SNARE complex and ultimately 
insulin exocytosis is not understood.  Currently, evidence suggests a role for F-actin (64), 
Gelsolin (143), Munc18c O-linked glycosylation and tyrosine phosphorylation (202, 282), Doc2b 
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(202), and S-nitrosylation in the activation of Syntaxin 4 (210).  There are other candidates, in 
particular Munc13-4, which may also regulate Syntaxin 4 activity.  Munc13-4 was recently found 
to interact with the H3 domains of Syntaxins 1 and 4 in vitro in a Ca
2+
-dependent manner (203).  
My results showed that Syntaxin 4-Gelsolin complex dissociation is dependent upon Ca
2+
 influx, 
but the mechanism behind this is unclear.  It is known that Ca
2+
 binding to Gelsolin causes a 
conformational change which allows Gelsolin to sever F-actin filaments (147).  Fortunately, a 
Ca
2+
-binding deficient mutant of Gelsolin exists and future studies using this mutant can help to 
elucidate the molecular mechanism of Syntaxin 4-Gelsolin dissociation (267).  Given that 
Syntaxin 1 and 4 have different roles in glucose-stimulated insulin secretion, it may be useful in 
the future to use bioinformatics analysis and mutagenesis to determine the residues which allow 
Syntaxin 4 to promote both phases of secretion and which restrict Syntaxin 1 to first phase.  
Additional studies might involve an analysis of differential binding proteins that exclusively 
regulate either Syntaxin 1 or 4.  Examples of this are already known, especially in the case of the 
Munc18-1-Syntaxin 1 and Munc18c-Syntaxin 4 complexes (198, 283).  Interestingly, there seems 
to be linkage between Syntaxin 4-Munc18c and Syntaxin 4-F-actin, as disruption of F-actin with 
latrunculin disrupts Syntaxin 4-Munc18c complexes and Munc18c knockdown disrupts Syntaxin 
4-F-actin complexes (Oh and Thurmond, unpublished).  The implications of these effects on 
cortical F-actin remodeling and insulin secretion are currently under investigation.  Now that 
PAK1 is implicated as a potential regulator of Syntaxin 4-F-actin complexes future work will be 
required to determine whether ERK or another PAK1 effector is responsible for PAK1 regulation 
of Syntaxin-4-F-actin complexes.  My data point to the regulation of Syntaxin 4 activation being 
a complicated multifaceted event not solely regulated by just one protein.  
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4.2 CONCLUSION 
 
 Altogether, these findings expand our knowledge of the control of glucose-stimulated 
insulin secretion by the Cdc42-PAK1 signaling pathway and the Syntaxin 4-Gelsolin interaction.  
I have expanded the known signaling cascade supporting second phase GSIS by elucidating 
PAK1-MEK-ERK signaling and revealed this to be important to actin remodeling.  I have 
provided the first links of glucose-regulated Cdc42-PAK1 signaling to Syntaxin 4-F-actin 
dynamics.  This marks the first signaling cascade in the beta cell to be required for F-actin 
remodeling, insulin granule accumulation at the PM, and SNARE complexation.  These new 
interactions and linkages provide new facets of GSIS to target for therapeutic gain. 
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